Indication Atlas — 851 Indications Tiered by Opportunity

The bigger picture

851 scored today — a slice of the resolver's reach

This view ranks the 851 indications that already carry active drug programmes in our data. The same pipeline extends much further: our resolver has mapped 25,088 disease concepts, 16,698 of them high-confidence, and 7,517 already carry drug-evidence — the scored universe grows as more evidence is ingested and the commercial axis comes online.

851

Scored & ranked today

Evidence-backed indications with active programmes

7,517

Already carry drug-evidence

Near-term expansion of the scored set

16,698

High-confidence diseases

Auto-resolved, high-confidence disease concepts

25,088

Total resolved concepts

The full mapped catalogue behind this work

How the index is built

One index, six axes

Each disease scores 0–10 on an opportunity index — a weighted mean of six axes that together balance how under-served a disease is against how actionable it looks. Every number is computed from our own enrichment plus the public Open Targets Platform.

Therapy gap · 28%

Is there an effective therapy?

Combined clinical landscape (Open Targets + our own drug-evidence): candidates but no approval score by most advanced phase; approvals pull it down.

Tractability & genetics · 20%

Is the biology druggable and validated?

Open Targets genetic-association strength and per-target druggability (tractable modalities), blended with our own druggable-genome tier (T1/T2) for the disease's pipeline targets.

Prevalence / burden · 15%

How many are affected?

Orphanet prevalence class as a population-burden proxy, ordinal from ultra-rare to common.

Research activity · 15%

How well studied?

Open Targets literature co-occurrence volume (log-scaled) — a proxy for scientific attention and validation.

Pipeline momentum 12% programmes advancing vs terminated (where trial status is known) Pipeline whitespace 10% fewer active programmes scores higher Weights Therapy gap 28% · Tractability & genetics 20% · Prevalence / burden 15% · Research activity 15% · Pipeline momentum 12% · Pipeline whitespace 10%

Tiers indications band by opportunity index — Tier 1 (top ~20%), Tier 2 (next ~40%), Tier 3 (rest), mirroring a target-tiering system White-space a separate lens from competitive crowdedness (programme + sponsor counts); ★ blue-sky = Tier 1 and uncrowded Target tiers each indication carries its pipeline targets' druggability tiers (T1/T2/non-coding) — the bridge to the target-tiering framework

What this index does and does not include

The index deliberately balances two pulls: whitespace rewards diseases with few competing programmes, while momentum and research reward activity and validation — so a disease that is both under-served and biologically actionable rises highest. Gap and context axes (therapy, prevalence, whitespace, momentum) renormalise when a signal is missing. Tractability and research are positive-evidence axes: where no Open Targets node or druggable target resolves, they are floored rather than dropped, so an unstudied disease with no demonstrable druggable biology is not rewarded for the gap in our knowledge. Population burden rests on Orphanet alone (rare-disease-heavy); a commercial/deal axis is a planned addition. A research signal, not clinical guidance.

Therapeutic-area mix

Where the 851 indications sit

Distribution across our 16-value therapeutic-area vocabulary. Counts sum to more than 851 because many diseases carry more than one area.

Oncology183

Infectious Disease118

Rare/Genetic86

Immunology & Inflammation80

Gastroenterology69

Neurology/CNS64

Metabolic & Endocrine60

Cardiovascular59

Women's & Reproductive Health49

Respiratory48

Musculoskeletal41

Hematology36

Dermatology32

Nephrology/Urology30

Psychiatry24

Ophthalmology20

Highest opportunity · top 12

The strongest opportunities, in detail

The top 12 by opportunity index. Click any card (or any table row below) to open its full profile — the six-axis breakdown with the evidence behind each score, every programme and target we hold, and source links.

001

8.04Opportunity index · 0–10

Open Targets drugs 0 · approved 0 Genetic targets 826

Score axes · 0–10

Unmet9

Tract7.15

Prev–

Res6.8

Mom–

Space9.01

#1T1 ★

Subacute necrotizing encephalomyopathy

Neurology/CNS

No approved therapy yet; 1 programme in development. Top associated targets: MT-ND5, MT-ND1, MT-ND4, MT-ND6.

Programmes in our data

ModalitySmall Molecule(1)

Assets (1)SONLICROMANOL

Statusfurthest phase not recorded · 1 sponsor(s)

Open Targets MONDO Trials

002

7.71Opportunity index · 0–10

Open Targets drugs 2 · approved 0 Genetic targets 1890

Score axes · 0–10

Unmet7

Tract6.95

Prev–

Res9.86

Mom–

Space8.01

#2T1 ★

Drug Abuse

No approved therapy yet; 3 programmes in development, furthest at Phase 2. Top associated targets: ADH1B, GABRA2, GABRB2, GABRB1.

Programmes in our data

ModalitySmall Molecule(3)

Assets (3)METFORMIN HYDROCHLORIDE; ACYCLOVIR; ACYCLOVIR SODIUM

Statusfurthest phase not recorded · 2 sponsor(s)

Trials

003

7.4Opportunity index · 0–10

Open Targets drugs 0 · approved 0 Genetic targets 1006

Score axes · 0–10

Unmet9

Tract4.17

Prev–

Res7.66

Mom–

Space9.01

#3T1 ★

Skin ulcer due to varicose veins

Cardiovascular

No approved therapy yet; 1 programme in development. Top associated targets: ADRA1B, ADRA1D, ADRA1A, SCN10A.

Programmes in our data

MoAmodulator(1)

TargetsABCB5-positive mesenchymal stromal cells

Assets (1)Skin-derived ABCB5-positive Mesenchymal Stem cells

Statusfurthest phase not recorded · 1 sponsor(s)

Open Targets MONDO Trials

004

7.32Opportunity index · 0–10

Open Targets drugs 2 · approved 0 Genetic targets 4328

Score axes · 0–10

Unmet8.5

Tract4.79

Prev–

Res7.76

Mom–

Space8.43

#4T1 ★

Hypertension-Associated Pregnancy Disorder

CardiovascularWomen's & Reproductive Health

No approved therapy yet; 2 programmes in development, furthest at Preclinical / IND. Top associated targets: SLC12A3, CORIN, STOX1, FTO.

Programmes in our data

ModalitySmall Molecule(1)

Assets (1)PROGESTERONE

Statusfurthest phase not recorded · 1 sponsor(s)

Trials

005

7.31Opportunity index · 0–10

Open Targets drugs 1 · approved 0 Genetic targets 6818

Score axes · 0–10

Unmet6

Tract6.31

Prev–

Res8.19

Mom10

Space8.43

#5T1 ★

mitochondrial respiratory chain disorder

Respiratory

No approved therapy yet; 2 programmes in development, furthest at Phase 3. Top associated targets: POLG, AFG3L2, TWNK, RRM2B.

Programmes in our data

ModalitySmall Molecule(4)

MoAinhibitor(1); modulator(1)

TargetsMicrosomal Prostaglandin E Synthase-1; NAD(P)H quinone dehydrogenase 1

Assets (2)SONLICROMANOL; VATIQUINONE

Statusfurthest phase Phase 3 · 2 sponsor(s)

Trials

006

7.24Opportunity index · 0–10

Open Targets drugs 0 · approved 0 Genetic targets 837

Score axes · 0–10

Unmet8.5

Tract5.72

Prev–

Res5.73

Mom–

Space9.01

#6T1 ★

Progressive hearing loss

No approved therapy yet; 1 programme in development, furthest at Preclinical / IND. Top associated targets: GJB2, MYO7A, MYH9, KCNQ4.

Programmes in our data

ModalityGene Therapy(1)

MoAmodulator(1)

TargetsGJB2

Assets (1)GJB2-GT

Statusfurthest phase Preclinical / IND · 1 sponsor(s)

OMIM Trials

007

7.1Opportunity index · 0–10

Open Targets drugs 0 · approved 0 Genetic targets 1790

Score axes · 0–10

Unmet9

Tract4.03

Prev–

Res6.36

Mom–

Space9.01

#7T1 ★

Rare epilepsy

Neurology/CNSRare/Genetic

No approved therapy yet; 1 programme in development. Top associated targets: CSTB, NHLRC1, EPM2A, KCTD7.

Programmes in our data

ModalitySmall Molecule(1)

MoAmodulator(1)

TargetsKv3.1/3.2 potassium channels

Assets (1)AUT00206 x AUT00201

Statusfurthest phase not recorded · 1 sponsor(s)

Trials

008

7.1Opportunity index · 0–10

Open Targets drugs 0 · approved 0 Genetic targets 0

Score axes · 0–10

Unmet8.5

Tract8

Prev–

Res2

Mom–

Space9.01

#8T1 ★

Extensively Drug-Resistant Tuberculosis

OncologyInfectious Disease

No approved therapy yet; 1 programme in development, furthest at Preclinical / IND.

Programmes in our data

ModalitySmall Molecule(1)

MoAinhibitor(6); modulator(1)

TargetsEGFR; cereblon; BTK

Assets (1)AEV40154

Statusfurthest phase Preclinical / IND · 2 sponsor(s)

Open Targets MONDO Trials

009

7.07Opportunity index · 0–10

Open Targets drugs 1 · approved 0 Genetic targets 1510

Score axes · 0–10

Unmet7

Tract5.94

Prev7

Res7.48

Mom–

Space9.01

#9T1 ★

arrhythmogenic right ventricular cardiomyopathy

Cardiovascular1-5 / 10 000

No approved therapy yet; 1 programme in development, furthest at Phase 2. Top associated targets: RYR2, DSG2, JUP, DSP.

Programmes in our data

MoAgene therapy(1)

Targetsplakophilin 2

Assets (1)RP-A601

Statusfurthest phase Phase 1 · 1 sponsor(s)

Open Targets MONDO Trials

010

7.03Opportunity index · 0–10

Open Targets drugs 0 · approved 0 Genetic targets 0

Score axes · 0–10

Unmet8

Tract6.67

Prev–

Res2

Mom10

Space9.01

#10T1 ★

Recurrent Platinum-Resistant Ovarian Carcinoma

OncologyNeurology/CNSWomen's & Reproductive Health

No approved therapy yet; 1 programme in development, furthest at Phase 1.

Programmes in our data

MoAcell therapy(3)

TargetsB7-H3

Assets (1)Autologous Anti-B7-H3 CAR T Cells

Statusfurthest phase Phase 1 · 1 sponsor(s)

Trials

011

7.02Opportunity index · 0–10

Open Targets drugs 0 · approved 0 Genetic targets 0

Score axes · 0–10

Unmet9

Tract7.5

Prev–

Res2

Mom–

Space8.01

#11T1 ★

High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

OncologyMusculoskeletal

No approved therapy yet; 3 programmes in development.

Programmes in our data

ModalitySmall Molecule(1); Antibody(1)

MoAinhibitor(2)

TargetsCDK9; programmed cell death 1

Assets (3)ENITOCICLIB x PEMBROLIZUMAB; ENITOCICLIB; PEMBROLIZUMAB

Statusfurthest phase not recorded · 1 sponsor(s)

Trials

012

7.02Opportunity index · 0–10

Open Targets drugs 0 · approved 0 Genetic targets 0

Score axes · 0–10

Unmet9

Tract7.5

Prev–

Res2

Mom–

Space8.01

#12T1 ★

Primary combined hyperlipidemia

Metabolic & EndocrineRare/Genetic

No approved therapy yet; 3 programmes in development.

Programmes in our data

ModalityCombination(1); Antibody(1); Small Molecule(1)

MoAinhibitor(2)

Targetsproprotein convertase subtilisin/kexin type 9; 3-hydroxy-3-methylglutaryl-CoA reductase

Assets (3)Evolocumab x atorvastatin; EVOLOCUMAB; ATORVASTATIN

Statusfurthest phase not recorded · 1 sponsor(s)

Trials

Full ranked set · tiered

All 851 scored indications, tiered by opportunity

Sorted by index descending and banded into tiers (T1 top ~20%, T2 next ~40%, T3 the rest). Bars show five axes (0–10): unmet need, tractability & genetics, research, momentum and white-space. Click any row for the full profile. Showing the top 50.

#	Tier	Indication	Area	Index	Unmet	Tract.	Research	Momentum	Whitespace	Assets	Lead
1	T1 ★	Subacute necrotizing encephalomyopathy	Neurology/CNS	8.04	9	7.15	6.8	–	8.25	1	SONLICROMANOL
2	T1 ★	Drug Abuse		7.71	7	6.95	9.86	–	6.82	3	METFORMIN HYDROCHLORIDE
3	T1 ★	Skin ulcer due to varicose veins	Cardiovascular	7.4	9	4.17	7.66	–	8.25	1	Skin-derived ABCB5-positive Mesenchymal Stem cells
4	T1 ★	Hypertension-Associated Pregnancy Disorder	Cardiovascular	7.32	8.5	4.79	7.76	–	7.67	1	PROGESTERONE
5	T1 ★	mitochondrial respiratory chain disorder	Respiratory	7.31	6	6.31	8.19	10	7.23	2	SONLICROMANOL
6	T1 ★	Progressive hearing loss		7.24	8.5	5.72	5.73	–	8.25	1	GJB2-GT
7	T1 ★	Rare epilepsy	Neurology/CNS	7.1	9	4.03	6.36	–	8.25	1	AUT00206 x AUT00201
8	T1 ★	Extensively Drug-Resistant Tuberculosis	Oncology	7.1	8.5	8	2	–	7.81	1	AEV40154
9	T1 ★	arrhythmogenic right ventricular cardiomyopath	Cardiovascular	7.07	7	5.94	7.48	–	8.25	1	RP-A601
10	T1 ★	Recurrent Platinum-Resistant Ovarian Carcinoma	Oncology	7.03	8	6.67	2	10	8.25	1	Autologous Anti-B7-H3 CAR T Cells
11	T1 ★	High Grade B-Cell Lymphoma with MYC and BCL2 a	Oncology	7.02	9	7.5	2	–	7.26	3	ENITOCICLIB x PEMBROLIZUMAB
12	T1 ★	Primary combined hyperlipidemia	Metabolic & Endocrine	7.02	9	7.5	2	–	7.26	3	Evolocumab x atorvastatin
13	T1 ★	Recurrent Liposarcoma		7.01	7	8	2	10	8.25	1	BTX-A51
14	T1 ★	Acute phototoxic reaction		6.99	8.5	5.66	4.99	–	7.67	1	PRÉNUMBRA®
15	T1 ★	Congenital anomalies of kidney and urinary tra	Nephrology/Urology	6.94	9	3.42	6.42	–	8.25	1	REGEND 003
16	T1	Triple hit lymphoma	Oncology	6.93	9	7.67	2	–	5.83	7	IDP-121
17	T1 ★	Bipolar I disorder, most recent episode depres	Psychiatry	6.92	9	6.67	2	–	8.25	1	ARIPIPRAZOLE
18	T1 ★	Decompensated cirrhosis of liver	Gastroenterology	6.92	9	6.67	2	–	8.25	1	EMRICASAN
19	T1 ★	Malignant lymphoma of extranodal AND/OR solid	Oncology	6.92	9	6.67	2	–	8.25	1	CZ48
20	T1 ★	Non-Functioning Lung Neuroendocrine Tumor	Oncology	6.92	9	6.67	2	–	8.25	1	SPARTALIZUMAB
21	T1 ★	Schizophrenic prodrome	Psychiatry	6.92	9	6.67	2	–	8.25	1	ASPIRIN
22	T1 ★	PRKAG2-related cardiomyopathy	Cardiovascular	6.91	8.5	6.18	3.51	–	8.25	1	AOC 1072
23	T1 ★	Cholestatic hepatitis		6.88	8.5	7.5	2	–	7.23	2	AX-0810 x AX-1412
24	T1	Precursor B-lymphoblastic leukemia acute	Oncology	6.88	7	8.33	2	10	5.71	6	HY004
25	T1	Zika virus infectious disease	Infectious Disease	6.87	8	4.04	8.31	–	5.51	7	TELRATOLIMOD
26	T1	brainstem cancer	Oncology	6.87	7	5.38	6.22	10	5.95	1	CATEQUENTINIB
27	T1 ★	Prostate Carcinoma Metastatic in the Bone	Oncology	6.86	6	5.63	10	–	6.27	1	ENZALUTAMIDE
28	T1	Locally Recurrent Breast Carcinoma	Oncology	6.86	9	7.67	2	–	4.82	10	PACLITAXEL
29	T1 ★	Abnormal uterine bleeding due to uterine fibro	Women's & Reproductive Health	6.85	9	6.67	2	–	7.67	2	SHR7280
30	T1 ★	hereditary cancer	Oncology	6.84	9	2.35	7.35	–	8.25	1	GeneMate®
31	T1	thrombocytopaenia	Hematology	6.84	9	7.5	2	–	5.51	9	ELTROMBOPAG
32	T1 ★	Retinal Dystrophy	Ophthalmology	6.8	7	6.4	6.14	–	6.51	3	AAV-CNGB3 x AAV-CNGA3 x AAV-UPF1 x AAV-RPGR x AAV-RPE65 x AAV-AIPL1 x AAV-RDH12 x AAV-GAD x AAV-hAQP1
33	T1 ★	Autoimmune deficiency syndrome	Immunology & Inflammation	6.8	7	6.42	6.52	–	6.68	1	RF-GS04
34	T1	NK-cell lymphoma	Oncology	6.8	9	7.2	2	–	5.83	7	Brentuximab Vedotin x CYCLOPHOSPHAMIDE x PREDNISONE x DOXORUBICIN x VINCRISTINE
35	T1 ★	Menopause related conditions	Women's & Reproductive Health	6.79	9	6.67	2	–	6.82	3	PROGESTERONE
36	T1 ★	Intestinal Disorder	Gastroenterology	6.78	5	6.54	8.93	–	8.25	1	Compound Glutamin Enterosoluble Capsule
37	T1 ★	T-cell depletion		6.77	8	7.5	2	–	8.25	1	ABO-2015
38	T1 ★	Acute myocardial infarction of anterior wall	Cardiovascular	6.74	9	2.92	6.1	–	8.25	1	ABCIXIMAB
39	T1 ★	Acute leukemias	Oncology	6.73	8.5	6.67	2	–	8.25	1	ALA-101
40	T1 ★	Chronic pain following amputation		6.73	8.5	6.67	2	–	8.25	1	CA-051
41	T1 ★	Early-onset obesity	Metabolic & Endocrine	6.73	8.5	6.67	2	–	8.25	1	MeiraGTx-BDNF
42	T1 ★	Neuropsychiatric symptoms	Neurology/CNS	6.73	8.5	6.67	2	–	8.25	1	SUVN-L3307032
43	T1 ★	Other inflammatory disorders of penis	Immunology & Inflammation	6.73	8.5	6.67	2	–	8.25	1	SAN903
44	T1 ★	Other inflammatory liver diseases	Immunology & Inflammation	6.73	8.5	6.67	2	–	8.25	1	TP-317
45	T1 ★	Pre-B Acute Lymphoblastic Leukemia	Oncology	6.73	8.5	6.67	2	–	8.25	1	CD22-CAR-HSC
46	T1 ★	Zoster ocular disease	Ophthalmology	6.73	8.5	6.67	2	–	8.25	1	ADAM15 AbIMP
47	T1 ★	Carcinoid tumor of the small bowel	Oncology	6.72	9	4.79	4.39	–	6.5	4	PALTUSOTINE
48	T1	MISCELLANEOUS TUMORS	Oncology	6.72	8	8	2	–	5.75	4	GF-CART01
49	T1	gynecologic cancer	Oncology	6.68	7	6.55	8.85	5	4.07	1	Avutometinib x defactinib
50	T1 ★	erythrocyte disorder	Hematology	6.68	7	6.18	5.59	–	7.67	2	MITAPIVAT
51	T1 ★	Ocular inflammation	Immunology & Inflammation	6.65	8.5	4.13	5.64	–	6.51	3	IVIEW-1701
52	T1 ★	Batten Disease		6.65	8.5	6.67	2	–	7.23	2	RGX-181
53	T1	NUT Carcinoma	Oncology	6.64	6	5.42	8.75	10	1.74	4	ZEN-3694
54	T1 ★	Epidermal nevi		6.64	7	6	5.26	–	8.25	1	NEDOMETINIB
55	T1	B Acute Lymphoblastic Leukemia, Not Otherwise	Oncology	6.61	9	6.67	2	–	4.59	9	Anti-CD22 CAR-expressing T Lymphocytes x CYCLOPHOSPHAMIDE x FLUDARABINE
56	T1 ★	Other disorders of amino-acid metabolism	Metabolic & Endocrine	6.61	8.5	6.5	2	–	7.23	2	Di-substituted pyrazole compounds
57	T1	Epithelial tumors	Oncology	6.59	7	4.01	6.79	10	5.47	1	NG-641
58	T1 ★	myocardium disease	Cardiovascular	6.59	5	7.1	7.65	–	7.67	1	MYOTECT
59	T1 ★	aggressive cancer	Oncology	6.59	8.5	2.42	7.35	–	7.23	2	KB-001
60	T1 ★	Benign Recurrent Intrahepatic Cholestasis		6.57	9	3.85	4.9	–	6.5	4	LINERIXIBAT x URSODIOL
61	T1 ★	Complication of intravascular line		6.56	9	5.33	2	–	8.25	1	SIROLIMUS
62	T1 ★	Irregular sleep wake rhythm disorder		6.56	9	5.33	2	–	8.25	1	LEMBOREXANT
63	T1	Hematological neoplasm	Oncology	6.55	4.5	8.13	8.52	10	0.86	3	VVD-130850 x PEMBROLIZUMAB
64	T1 ★	Antibody-mediated rejection	Nephrology/Urology	6.54	8	6.67	2	–	8.25	1	CID-103
65	T1 ★	Primary Myelofibrosis with CALR Mutation	Oncology	6.54	8	6.67	2	–	8.25	1	INCA033989
66	T1 ★	chemotherapy-induced neuropathy	Neurology/CNS	6.54	8	6.67	2	–	8.25	1	CNTX 6016
67	T1 ★	Stress disorders		6.53	7	3.81	7.63	–	8.25	1	SPC-15
68	T1 ★	Hantavirus Infections		6.53	7	4.58	6.58	–	8.25	1	FX06
69	T1	Hashimoto Disease	Immunology & Inflammation	6.52	6	5.9	8.58	–	5.37	1	LINSITINIB
70	T1	Systemic Inflammatory Response Syndrome	Immunology & Inflammation	6.5	6	4.92	7.24	10	4.95	1	RILDINADSTROCEL
71	T1 ★	Venezuelan equine encephalitis virus infection	Neurology/CNS	6.5	9	2.78	5.12	–	8.25	1	V4020
72	T1 ★	Subcutaneous Tissue	Oncology	6.49	7	4.96	5.9	–	8.25	1	ANK-101 x CEMIPLIMAB
73	T1 ★	muscular dystrophy-dystroglycanopathy	Musculoskeletal	6.49	8.5	4.6	3.6	–	8.25	1	MLAB-002
74	T1 ★	Polyneuropathy due to diabetes mellitus	Metabolic & Endocrine	6.48	9	5.33	2	–	7.67	2	CEBRANOPADOL
75	T1 ★	Parkinson's disease with dyskinesia	Neurology/CNS	6.46	8.5	3.44	4.46	–	8.25	1	CSTI-200
76	T1	Fuchs' endothelial dystrophy	Ophthalmology	6.45	7	5.17	6.29	–	5.95	4	SCO-116
77	T1 ★	Capillary Malformation-Arteriovenous Malformat	Cardiovascular	6.45	8.5	4.42	3.61	–	8.25	1	GPX-Clear Embolic Device
78	T1 ★	Resistant hypertensive disorder	Cardiovascular	6.44	6	5.33	7.68	–	7.26	1	SZ005
79	T1 ★	Adenovirus Infection	Infectious Disease	6.43	9	3.06	4.39	–	8.25	1	Adenovirus Vaccine
80	T1	hematopoietic/lymphoid cancer	Oncology	6.43	7	8.75	2	–	4.47	8	ABO-2015
81	T1	Prematurity of infant	Ophthalmology	6.42	6	5.53	8.41	–	3.39	5	IBUPROFEN
82	T1 ★	hypertension in pregnancy	Cardiovascular	6.42	5	6.39	7.76	–	7.67	1	Gravidol
83	T1 ★	monogenic disease	Metabolic & Endocrine	6.42	7	6.11	4.67	–	6.82	1	FBX-201
84	T1 ★	Chronic inflammatory disorders of orbit	Immunology & Inflammation	6.42	8	6.5	2	–	7.67	2	FT751
85	T1 ★	Chronic nonalcoholic liver disease	Gastroenterology	6.37	8.5	5.33	2	–	8.25	1	17-β-HSD-13 inhibitor
86	T1 ★	Hand-Foot Syndrome	Rare/Genetic	6.36	6	4.89	7.9	–	7.26	1	Proprietary Lead Compound
87	T1	Metastatic Prostatic Adenocarcinoma	Nephrology/Urology	6.35	7	5.83	5.85	–	5.13	3	Abscopal 1001
88	T1 ★	Takotsubo syndrome	Cardiovascular	6.34	7	4.79	8.07	–	6.27	1	GRK5 Inhibitor
89	T1 ★	Encephalopathies	Neurology/CNS	6.34	6	6.39	5.79	–	6.51	3	BL-001
90	T1	Bone cancer	Oncology	6.33	4.5	6.8	8.97	–	5.81	1	Denosumab Biosimilar
91	T1	Benign neoplasm of prostate	Oncology	6.32	6	5.92	7.12	–	5.35	8	DUTASTERIDE
92	T1 ★	Malignant Thoracic Neoplasm	Oncology	6.31	8	6.3	6.43	0	8.25	1	ENRISTOMIG
93	T1 ★	Aortic aneurysms and dissections	Cardiovascular	6.28	9	2.6	4.31	–	8.25	1	ULINASTATIN x THYMALFASIN
94	T1 ★	Fibrinogen deficiency	Hematology	6.27	7	4.33	5.68	–	8.25	1	FIBRINOGEN, HUMAN
95	T1	Lung Diseases	Immunology & Inflammation	6.25	5	6.12	9.26	–	2.89	3	UPAMOSTAT
96	T1 ★	Chronic HIV infection	Immunology & Inflammation	6.25	7	5.21	4.31	–	7.26	1	LERONLIMAB
97	T1	Severe asthma	Cardiovascular	6.25	6	4.61	7.52	10	4.95	1	DEPEMOKIMAB
98	T1 ★	Septal defect	Cardiovascular	6.24	5	4.51	8.23	–	8.25	1	Ultrasept Cribriform Device
99	T1	Obstructive cardiomyopathy	Cardiovascular	6.24	4	7.78	9.1	–	4.37	1	DEXPROPRANOLOL
100	T1	pulmonary heart disease	Cardiovascular	6.23	5	6.13	9.6	–	3.59	2	NOGMT-based Products
101	T1	Steatohepatitis	Metabolic & Endocrine	6.23	6	5.85	9.38	–	2.18	1	SNA-003
102	T1 ★	Bone hyperplasia	Musculoskeletal	6.22	9	3.13	8.5	–	8.25	1	Tiao Gu Pian
103	T1	Dyskinesia		6.22	7	5.91	5.73	5	4.59	8	AMANTADINE HYDROCHLORIDE
104	T1 ★	Adult Pure Erythroid Leukemia	Oncology	6.21	9	1.38	5.59	–	8.25	1	CYTARABINE x CLOFARABINE x FILGRASTIM x DILANUBICEL
105	T1	Giant Cell Tumors	Oncology	6.2	7	4.79	6.45	–	5.69	1	HY035
106	T1 ★	Fibrotic lymphadenopathy		6.2	8.5	5	2	–	6.92	2	OPK-88006
107	T1 ★	Myoclonic disorder		6.19	8.5	3.96	2.95	–	8.25	1	RC-001
108	T1 ★	Eosinophilic Endomyocardial Disease	Cardiovascular	6.17	8	5.33	2	–	8.25	1	YH35324
109	T1 ★	Malignant neoplasm of cardio-esophageal juncti	Oncology	6.17	8	5.33	2	–	8.25	1	JZP898
110	T1	Pulmonary hypertension due to interstitial lun	Cardiovascular	6.16	5	5.7	9.26	–	3.64	1	RT234-ILD PH
111	T1 ★	Anemia of chronic inflammation	Immunology & Inflammation	6.16	7	6.67	2	–	8.25	1	DISC-0974
112	T1 ★	Aspirin-exacerbated respiratory disease	Respiratory	6.16	7	6.67	2	–	8.25	1	IFETROBAN
113	T1 ★	Behçet's disease		6.16	7	6.67	2	–	8.25	1	PENTOXIFYLLINE
114	T1 ★	Hypoglycemia, leucine-induced	Metabolic & Endocrine	6.16	7	6.67	2	–	8.25	1	Baqsimi
115	T1 ★	PF-ILD-progressive fibrosing interstitial lung	Infectious Disease	6.16	7	6.67	2	–	8.25	1	PARIDIPRUBART
116	T1 ★	question whether diagnosed with Crohn’s diseas	Immunology & Inflammation	6.16	7	6.67	2	–	8.25	1	AGMB-129
117	T1 ★	Inflammatory disorder of the respiratory tract	Immunology & Inflammation	6.12	8.5	5.92	0	–	8.25	1	TRPV4 antagonist
118	T1	Chronic Migraine	Neurology/CNS	6.12	6	5.32	7.22	–	5.69	1	ALMA Lens
119	T1	Metastatic Liposarcoma	Oncology	6.11	4.5	6.08	8.24	10	3.76	1	BTX-A51
120	T1	diabetic macular edema	Cardiovascular	6.11	3	6.59	9.63	10	3.18	1	EOM147
121	T1 ★	B-cell neoplasm		6.1	5	5.53	6.96	–	8.25	1	SG299
122	T1	heart valve disease	Cardiovascular	6.1	5	5.45	8.86	–	5.57	2	TaurusWave
123	T1	childhood cancer	Oncology	6.1	5	6	8.64	–	2.97	17	NY-303
124	T1	Acute bronchiolitis caused by respiratory sync	Infectious Disease	6.09	6	4.81	8.53	–	4.47	1	V-306
125	T1	Pulmonary Heart Disease	Cardiovascular	6.08	5	5.59	9.6	–	4.03	1	CardiALLO
126	T1 ★	Bone metabolism disorders	Metabolic & Endocrine	6.08	5	6.45	6.31	–	6.82	3	Osteoprotegerin ELISA
127	T1 ★	fetal and neonatal alloimmune thrombocytopenia	Hematology	6.07	7	3.62	4.69	–	8.25	1	RLYB212
128	T1	Stimulant use disorder		6.07	6	6.44	6.76	–	2.73	5	SBS-518
129	T1 ★	Meningitis caused by echovirus	Infectious Disease	6.06	8.5	2.5	4.28	–	8.25	1	OG716
130	T1	regional pain syndrome	Rare/Genetic	6.05	6	4.59	7.79	–	4.33	2	HZT-501
131	T1 ★	Chronic motor tic disorder		6.05	6	5.42	5.7	–	7.26	1	ELCUBRAGISTAT
132	T1	Chronic coronary syndrome	Cardiovascular	6.03	6	4.5	8.72	–	3.67	4	PRASUGREL HYDROCHLORIDE
133	T1	Proliferative retinopathy due to diabetes mell	Metabolic & Endocrine	6.02	6	4.78	8.12	–	4.63	1	BI 764524
134	T1	myeloid neoplasm	Oncology	6.01	6	5.3	8.08	–	3.14	2	FCN-338
135	T1	metabolic dysfunction-associated steatohepatit	Metabolic & Endocrine	6.01	6	5.03	9.38	–	2.18	1	LOY-002
136	T1 ★	Steroid-resistant nephrotic syndrome	Immunology & Inflammation	6.01	7	4.14	5.72	–	6.68	1	IDX9054
137	T1 ★	Malignant neoplasm in full remission	Oncology	6.01	9	3.33	2	–	8.25	1	TRX103
138	T1 ★	Other disorders of brain	Immunology & Inflammation	6.01	9	3.33	2	–	8.25	1	PEArlboost
139	T1 ★	Tracheostomy infection	Infectious Disease	6.01	9	3.33	2	–	8.25	1	Antimicrobial Tracheostomy Tube
140	T1 ★	Inflammatory liposarcoma	Immunology & Inflammation	6.0	6	3.75	7.67	–	7.26	1	IRX-4204
141	T1 ★	Delayed sleep-phase syndrome	Psychiatry	6.0	6	7.5	2	–	8.25	1	TASIMELTEON
142	T1 ★	Response Evaluation Criteria in Solid Tumors	Oncology	5.99	7	6.67	2	5	8.25	1	B7-H3 CAR T cells; SJCARB7H3_41BBL infusion
143	T1 ★	ampullary cancer	Oncology	5.98	7	6.67	2	–	6.5	4	ONVANSERTIB
144	T1 ★	Endophthalmitis	Infectious Disease	5.97	7	1.81	8.46	–	6.94	1	iFAST AST Platform
145	T1	Radiation-induced mucositis		5.97	5	8.33	2	8.75	4.31	10	GM-1111
146	T1	Epithelial neoplasm	Oncology	5.96	6	3.79	6.65	10	5.03	1	NG-641
147	T1	B-Cell Leukemia	Oncology	5.96	7	5.35	6.58	10	3	16	CC312
148	T1	Inflammatory Bowel Diseases	Gastroenterology	5.96	4	7	10	–	2.59	1	Ezrin peptides
149	T1	Chronic inflammatory disorder	Immunology & Inflammation	5.95	5	5.42	7.53	–	4.95	1	BARICITINIB
150	T1 ★	respiratory tract injury	Respiratory	5.95	5	4.58	7.49	–	6.68	1	Recombinant Hemopexin
151	T1 ★	Chronic ulcer of foot		5.95	8	2.9	5.11	–	8.25	1	AMINOLEVULINIC ACID
152	T1	Advanced retinal disease	Neurology/CNS	5.95	6	3.32	8.97	–	3.96	10	CG-EY1
153	T1	Fibrotic lung disease	Respiratory	5.94	5	4.73	9.26	–	3.64	1	ME-015
154	T1	Lung disease	Infectious Disease	5.94	5	4.73	9.26	–	3.64	1	BV500
155	T1 ★	Sexual desire disorder	Psychiatry	5.94	5	5	6.92	–	8.25	1	Libicare
156	T1	Primary fibromyalgia syndrome	Immunology & Inflammation	5.94	6	6.71	2	9.58	2.84	18	TELITACICEPT
157	T1	Type 1 Diabetes Mellitus with Hypoglycemia wit	Metabolic & Endocrine	5.94	7	6.67	2	–	5.93	5	ZT-01
158	T1 ★	thromboembolic disease		5.92	5	5.34	7.56	–	6.02	1	SKB336
159	T1 ★	Device related infection	Infectious Disease	5.92	8.5	2.95	2.98	–	8.25	1	CYCLOSPORINE
160	T1 ★	Precancerous lesions	Infectious Disease	5.92	8.5	4	2	–	7.23	2	PVX-8
161	T1 ★	Acquired angioedema	Immunology & Inflammation	5.91	6	4.03	5.8	10	7.81	1	DEUCRICTIBANT
162	T1	Immune System Diseases	Immunology & Inflammation	5.91	5	6.44	6.15	–	5.83	1	MDI-0355 x MOD-C x MOD-D x ALVX-A
163	T1	Macular dystrophy	Ophthalmology	5.91	4.5	4.26	9.39	10	2.25	2	AMTX-100 CF3
164	T1	Acute allergic reaction	Immunology & Inflammation	5.91	5	5.76	8.62	–	3.52	2	IsiCort
165	T1 ★	Lipid Disorders		5.9	8.5	5.43	0	–	7.23	2	Fatostatin
166	T1 ★	Parainfluenza Virus Infection	Infectious Disease	5.9	5	5	6.72	–	8.25	1	ELRE081 Influenza virus
167	T1	Systemic candida	Infectious Disease	5.9	5	4.98	8.87	–	5.03	1	FLUCONAZOLE
168	T1	Congenital immunodeficiency disease	Immunology & Inflammation	5.89	4.5	5.59	9.6	–	4.03	1	Thymopolypeptides for Injection
169	T1	congenital metabolic disease	Cardiovascular	5.89	4.5	5.59	9.6	–	4.03	1	PAROMOMYCIN SULFATE
170	T1 ★	Vascular skin abnormality	Dermatology	5.89	5	3.75	8.31	–	8.25	1	SIROLIMUS
171	T2	Fatigue Syndrome, Chronic	Neurology/CNS	5.89	6	4.5	8.72	5	3.98	2	NORKETOTIFEN
172	T2	Inflammatory joint disease	Oncology	5.87	3.5	7.34	10	–	2.15	2	PrTrispan
173	T2	Atherosclerosis obliterans	Infectious Disease	5.87	6	4.58	7.89	–	4.28	1	CLBS12
174	T2	Metastatic malignant neoplasm to soft tissues	Oncology	5.87	9	3.33	2	–	7.26	3	ANK-101 x CEMIPLIMAB
175	T2	Rare disease		5.87	7	7.45	2	–	2.08	25	MDI-0355 x MOD-C x MOD-D x ALVX-A
176	T2	Malignant neoplasms	Oncology	5.85	4.5	6.4	8.64	–	0.68	51	JS201
177	T2	Tick-Borne Diseases	Infectious Disease	5.85	5	3.92	7.91	–	8.25	1	pGOLD multiplexed assay kits
178	T2	Secondary narcolepsy	Neurology/CNS	5.85	3	5.77	7.95	10	5.11	1	SERDEXMETHYLPHENIDATE
179	T2	Glioblastoma		5.84	4	5.72	10	10	0.47	1	BDTX-1535 x BDTX-4933
180	T2	Radiation fibrosis - lung	Neurology/CNS	5.84	4.5	5.63	9.72	–	3.45	1	ALT-100
181	T2	MALIGNANCIES	Oncology	5.84	7	6.67	2	–	4.31	9	CN1
182	T2	Melanoma In Situ	Oncology	5.83	6	4.17	6.25	–	7.26	1	Sofusa® DoseConnect™
183	T2	Bacteremia caused by Methicillin resistant Sta		5.83	9	3.33	2	–	6.5	4	EXEBACASE
184	T2	Campylobacter Infections		5.82	8.5	3.33	2	–	8.25	1	Campylobacter Vaccine
185	T2	Infectious bursal disease		5.82	8.5	3.33	2	–	8.25	1	Poultry Vaccine
186	T2	Neutrophilic disorder	Dermatology	5.82	8.5	3.33	2	–	8.25	1	KP301
187	T2	OL(1)p53	Oncology	5.82	8.5	3.33	2	–	8.25	1	CL04177 x CL04183
188	T2	Microangiopathy	Cardiovascular	5.81	5	5.07	8.09	–	5.37	1	CALCIUM DOBESILATE
189	T2	H1N1 Flu (Swine Flu)		5.81	6	2.62	8.23	–	7.26	1	RNAi-based Treatment for Swine Flu
190	T2	B and T cell defects		5.8	5	5.31	4.59	–	8.25	1	Thymopeptide Enteric-coated Capsules
191	T2	T-cell deficiency		5.8	5	5.31	4.59	–	8.25	1	Thymopeptide Enteric-coated Tablets
192	T2	Brain Injury		5.79	5	4.92	9.76	–	3.06	1	PolarCap® System
193	T2	Pain lumbosacral	Musculoskeletal	5.79	5	5	6.54	–	7.67	1	Bals Sulphur Gel
194	T2	disc prolapse		5.78	6	3.28	8.1	–	5.95	1	Cytotron
195	T2	Thromboangiitis	Cardiovascular	5.77	4.5	4.79	7.09	–	6.68	1	ARGATROBAN
196	T2	Chronic inflammatory demyelinating polyradicul	Immunology & Inflammation	5.77	5	4.63	7.53	–	2.84	12	Flusalazine
197	T2	Typical Teratoid Rhabdoid Tumor	Oncology	5.77	6	6.19	6.21	–	3.59	2	Otviciclib
198	T2	Psoriasis-related juvenile idiopathic arthriti	Immunology & Inflammation	5.77	6	6.04	4.59	–	5.57	2	ADALIMUMAB
199	T2	Chronic pain following repair of hernia		5.77	6	6.67	2	–	8.25	1	ROPIVACAINE
200	T2	EGFR Exon 20 Insertion Mutation		5.77	6	6.67	2	–	9.01	1	FIRMONERTINIB
201	T2	Free-living amoeba infection	Infectious Disease	5.77	6	6.67	2	–	8.25	1	NITROXOLINE
202	T2	Genetic obesity disorder	Metabolic & Endocrine	5.77	6	6.67	2	–	8.25	1	SETMELANOTIDE
203	T2	High Grade B-Cell Lymphoma with MYC and BCL2 R	Oncology	5.77	6	6.67	2	–	8.25	1	GOLCADOMIDE
204	T2	Lower extremities ulcers of	Cardiovascular	5.77	6	6.67	2	–	8.25	1	PUDK-HGF
205	T2	Residual Disease	Oncology	5.77	6	6.67	2	–	8.25	1	DATOPOTAMAB DERUXTECAN
206	T2	mitochondrial disease/disorder		5.77	6	6.67	2	–	8.25	1	SONLICROMANOL
207	T2	SYNGAP1-related developmental and epileptic en	Neurology/CNS	5.76	8.5	6.67	2	–	8.25	1	PRAX-090
208	T2	MELAS Syndrome	Psychiatry	5.75	4.5	5.72	9.9	–	2.34	1	SONLICROMANOL
209	T2	Diffuse Glioma	Oncology	5.75	6	5.57	6.87	–	2.95	1	SAFUSIDENIB
210	T2	Mixed Phenotype Acute Leukemia	Oncology	5.75	6	6.17	5.62	–	2.92	9	ZIFTOMENIB
211	T2	Mood Disorders	Psychiatry	5.75	5	8	2	–	8.25	1	PIRACETAM
212	T2	Granulomatous polyangiitis	Cardiovascular	5.73	4.5	5.02	8.14	–	4.28	3	FLUDARABINE x CYCLOPHOSPHAMIDE
213	T2	Pancreatic Undifferentiated Carcinoma	Oncology	5.73	5	4.38	10	–	3.31	1	AVOTACICLIB
214	T2	Congestion		5.73	5	3.72	7.59	–	8.25	1	Lymphomyosot
215	T2	Major depressive disorder, recurrent episode	Psychiatry	5.73	6	6.5	2	–	8.25	1	SEP-4199
216	T2	Eye disorders	Immunology & Inflammation	5.72	6	3.85	5.5	–	8.25	1	PEArlboost
217	T2	SKIN DISORDERS	Immunology & Inflammation	5.72	6	3.85	5.5	–	8.25	1	PEArlboost
218	T2	Arthritis, Juvenile	Immunology & Inflammation	5.72	5	5.96	5.89	–	5.27	4	SARILUMAB
219	T2	hidradenitis suppurativa	Infectious Disease	5.7	5	6.2	7.61	–	3	1	BGB-45035
220	T2	Metastatic Breast Carcinoma in the Skin	Oncology	5.69	6	5	7.5	–	3.76	1	REM-001
221	T2	Hepatic cancer	Oncology	5.69	4	6.05	10	–	2.49	1	VEBRELTINIB
222	T2	Erectile dysfunction due to endocrine disease	Ophthalmology	5.69	6	6.67	2	–	7.23	2	GW-870086
223	T2	Urinary System	Infectious Disease	5.68	3	6.35	8.46	–	6.5	2	Lysine Acetylsalicylate for Injection 0.25g
224	T2	Thyroid nodules	Metabolic & Endocrine	5.68	5	2.82	8.54	–	8.25	1	mir-THYpe
225	T2	Pulmonary congestion		5.68	5	3.53	7.59	–	8.25	1	GUAIFENESIN
226	T2	Associated with other malignancies	Oncology	5.68	8.5	3.33	2	–	6.51	3	TABELECLEUCEL
227	T2	Pain disorders		5.67	6	2.92	7.79	–	3.89	2	THC knockout Program
228	T2	aortic disease	Cardiovascular	5.66	5	4.34	9.05	–	4.28	1	Thoraflex™ Hybrid device
229	T2	Primary Immunodeficiency Diseases	Immunology & Inflammation	5.65	5	4.82	7.43	–	4.93	1	OpCT-001
230	T2	Acute suppurative otitis media		5.65	9	1.25	3.42	–	7.67	2	TELITHROMYCIN
231	T2	ADHD, predominantly inattentive type		5.65	9	2	2	–	8.25	1	Metadoxine
232	T2	Acute headache due to craniotomy		5.65	9	2	2	–	8.25	1	BUPIVACAINE HYDROCHLORIDE x DEXMEDETOMIDINE
233	T2	Amanita poisoning		5.65	9	2	2	–	8.25	1	Silybin
234	T2	Anastomotic infection	Infectious Disease	5.65	9	2	2	–	8.25	1	VORICONAZOLE
235	T2	Aspirin exacerbated respiratory disease	Respiratory	5.65	9	2	2	–	8.25	1	IFETROBAN
236	T2	Back muscle spasms		5.65	9	2	2	–	8.25	1	TOLPERISONE
237	T2	Bacterial enteritis of intestine	Infectious Disease	5.65	9	2	2	–	8.25	1	OPS-2071
238	T2	Bacterial infection due to streptococcus, grou	Infectious Disease	5.65	9	2	2	–	8.25	1	GBS Vaccine
239	T2	Bipolar I disorder, most recent episode manic	Psychiatry	5.65	9	2	2	–	8.25	1	KarXT x Lithium cation x Valproate x LAMOTRIGINE
240	T2	Bipolar disorder, most recent episode depressi	Psychiatry	5.65	9	2	2	–	8.25	1	ALTO-100
241	T2	Chronic kidney disease due to type 1 diabetes	Metabolic & Endocrine	5.65	9	2	2	–	8.25	1	BARDOXOLONE METHYL
242	T2	Chronic pain due to malignant neoplastic disea	Oncology	5.65	9	2	2	–	8.25	1	QIXLEEF
243	T2	Chronic radiation ulcer		5.65	9	2	2	–	8.25	1	Fibrin Sealant (Tisseel)
244	T2	Clear cell adenocarcinoma of peritoneum	Oncology	5.65	9	2	2	–	8.25	1	LORIGERLIMAB
245	T2	Cushing disease due to increased ACTH secretio	Oncology	5.65	9	2	2	–	8.25	1	CLOFUTRIBEN
246	T2	Depressive disorder in remission	Psychiatry	5.65	9	2	2	–	8.25	1	PLOSARACETAM
247	T2	Destruction		5.65	9	2	2	–	8.25	1	RF-based Body Contouring & Fat Destruction Platform
248	T2	Dyskinetic syndrome	Rare/Genetic	5.65	9	2	2	–	8.25	1	VALBENAZINE TOSYLATE
249	T2	Edematous skin	Dermatology	5.65	9	2	2	–	8.25	1	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
250	T2	Endometriosis externa	Women's & Reproductive Health	5.65	9	2	2	–	8.25	1	LINIFANIB x AFATINIB x AXITINIB
251	T2	Extravasation injury		5.65	9	2	2	–	8.25	1	Vedette®
252	T2	FIGO Grade 1 Endometrial Endometrioid Adenocar	Oncology	5.65	9	2	2	–	8.25	1	TIRZEPATIDE
253	T2	Fracture of metatarsal bone	Musculoskeletal	5.65	9	2	2	–	8.25	1	Photodynamic Bone Stabilization System
254	T2	Fracture of phalanx of foot		5.65	9	2	2	–	8.25	1	Photodynamic Bone Stabilization System
255	T2	Gingival disease due to dental plaque		5.65	9	2	2	–	8.25	1	CETYLPYRIDINIUM CHLORIDE x Zinc cation x Dentalfluoro
256	T2	Hemophilic arthropathy	Hematology	5.65	9	2	2	–	8.25	1	PTI-101
257	T2	Herpes simplex type 2 infection	Infectious Disease	5.65	9	2	2	–	8.25	1	VALACYCLOVIR
258	T2	Immune effector cell-associated HLH-like syndr	Rare/Genetic	5.65	9	2	2	–	8.25	1	RUXOLITINIB
259	T2	Infection by Schistosoma	Infectious Disease	5.65	9	2	2	–	8.25	1	PRAZIQUANTEL, (R)-
260	T2	Landouzy-Dejerine syndrome	Rare/Genetic	5.65	9	2	2	–	8.25	1	AOC-1020
261	T2	Long-chain 3-hydroxy-acyl-CoA dehydrogenase de		5.65	9	2	2	–	8.25	1	TRIHEPTANOIN
262	T2	Loss of teeth due to trauma, extraction, or pe		5.65	9	2	2	–	8.25	1	Adipearl
263	T2	Lymphoma, Non-Hodgkin	Oncology	5.65	9	2	2	–	8.25	1	FE 203799
264	T2	Memory defects		5.65	9	2	2	–	8.25	1	Aralia ginseng root x GINKGO
265	T2	Mixed venous and arterial		5.65	9	2	2	–	8.25	1	ADRC technology
266	T2	Mucor infection	Infectious Disease	5.65	9	2	2	–	8.25	1	YiGanKang Injection
267	T2	Myelodysplastic/Myeloproliferative Neoplasm wi	Oncology	5.65	9	2	2	–	8.25	1	ROPEGINTERFERON ALFA-2B
268	T2	Pain due to neoplastic disease	Oncology	5.65	9	2	2	–	8.25	1	METHADONE HYDROCHLORIDE
269	T2	Pancreatic Diseases	Gastroenterology	5.65	9	2	2	–	8.25	1	BAB-803
270	T2	Peripheral angiopathy due to diabetes mellitus	Metabolic & Endocrine	5.65	9	2	2	–	8.25	1	ASPIRIN
271	T2	Post-COVID syndrome	Infectious Disease	5.65	9	2	2	–	8.25	1	Convalescent Serum Therapy
272	T2	Postoperative infection (disorder)	Infectious Disease	5.65	9	2	2	–	8.25	1	CEFAZOLIN
273	T2	Primary haemophagocytic lymphohistiocytosis		5.65	9	2	2	–	8.25	1	EMAPALUMAB
274	T2	Pseudomonal infections	Infectious Disease	5.65	9	2	2	–	8.25	1	AZITHROMYCIN
275	T2	Reduced ejection fraction co-occurrent and due	Cardiovascular	5.65	9	2	2	–	8.25	1	APD418
276	T2	SCN8A-related epilepsy with encephalopathy	Neurology/CNS	5.65	9	2	2	–	8.25	1	RELUTRIGINE
277	T2	Scoliosis, early-onset, severe	Musculoskeletal	5.65	9	2	2	–	8.25	1	Magnetically Growing Rod
278	T2	Septic coagulopathy		5.65	9	2	2	–	8.25	1	THROMBOMODULIN ALFA
279	T2	Small cell carcinoma of the ovary, hypercalcem	Oncology	5.65	9	2	2	–	8.25	1	TAZEMETOSTAT
280	T2	Statin-induced myopathy	Musculoskeletal	5.65	9	2	2	–	8.25	1	ROSUVASTATIN
281	T2	Tear disorder		5.65	9	2	2	–	8.25	1	Systane Lubricant
282	T2	Trochanteric syndrome	Rare/Genetic	5.65	9	2	2	–	9.01	1	AUTOLOGOUS PLATELET RICH PLASMA
283	T2	Urgency-frequency syndrome	Nephrology/Urology	5.65	9	2	2	–	8.25	1	Oxybutynin x Oxybutynin x Oxybutynin x Oxybutynin x Solifenacin x Tolterodine x Tolterodine x Trospium x Darifenacin x Fesoterodine
284	T2	Varicose veins of lower extremity		5.65	9	2	2	–	9.01	1	CALCIUM DOBESILATE
285	T2	White spot lesions of teeth		5.65	9	2	2	–	8.25	1	OrthoClean
286	T2	Antibody deficiency	Immunology & Inflammation	5.64	5	6.4	7.24	–	6.68	1	IVIG
287	T2	Skin lesions	Dermatology	5.63	5	3.99	6.73	–	8.25	1	RenuDermcell
288	T2	Metastatic Malignant Neoplasm	Oncology	5.63	4.5	6.56	9.09	–	0	310	PEMBROLIZUMAB
289	T2	Invasive pneumococcal disease		5.63	8	3.33	2	–	8.25	1	RVX-001
290	T2	Other forms of heart disease		5.63	8	3.33	2	–	8.25	1	Kylo-0603
291	T2	reproductive organ	Infectious Disease	5.62	5	4.47	8.85	–	4.07	1	AZITHROMYCIN
292	T2	Prosthesis-Related Infections	Infectious Disease	5.62	8	2.57	2.98	–	8.25	1	Non-contact Induction Heating Device
293	T2	Digestive System Diseases	Gastroenterology	5.62	5	7.5	2	–	8.25	1	Pancreatin Enteric-coated Tablets
294	T2	Genetic Diseases, Inborn		5.62	8.5	3.67	2	–	4.47	8	LEOPARD
295	T2	Other peripheral vertigo		5.62	5	8	2	–	6.82	3	Arlevert
296	T2	Primary apnea of premature newborns		5.62	5	7.5	2	–	8.25	1	CAFFEINE CITRATE
297	T2	Primary apnoea of premature newborns		5.62	5	7.5	2	–	8.25	1	CAFFEINE CITRATE
298	T2	Primary Open Angle Glaucoma	Ophthalmology	5.61	5	5	5.67	–	7.23	2	BETAXOLOL
299	T2	Zika Virus Infection	Infectious Disease	5.6	5	1.67	8.31	–	8.25	1	Nobivac
300	T2	Acute pain due to injury		5.6	4.5	5.19	10	–	2.11	1	Mericaine 4% Gel
301	T2	Enteropathy	Immunology & Inflammation	5.6	7	1.95	5.98	–	7.67	1	EnteroTracker®
302	T2	Advanced Biliary Tract Carcinoma	Oncology	5.58	6	4.45	8.59	–	3.02	1	ST-01156
303	T2	developmental and epileptic encephalopathy, 14	Neurology/CNS	5.58	8.5	3.86	1.2	–	5.93	5	ABS-1230
304	T2	Generalized keratoacanthoma	Oncology	5.58	9	0.42	3.8	–	8.25	1	DARLEUKIN x ONFEKAFUSP ALFA
305	T2	Chronic kidney disease due to type 2 diabetes	Metabolic & Endocrine	5.58	6	3.33	2	10	8.25	1	rilparencel
306	T2	Acute GVH disease		5.57	9	2	2	–	7.23	2	IVARMACITINIB
307	T2	Burns of multiple sites		5.57	9	2	2	–	7.23	2	MTX-001
308	T2	EBV-Related Lymphoma	Oncology	5.57	9	2	2	–	7.23	2	TABELECLEUCEL
309	T2	Haemodialysis complication		5.57	9	2	2	–	7.67	2	Crude heparin
310	T2	Intraepithelial neoplasia due to human papillo	Oncology	5.57	9	2	2	–	7.23	2	Recombinant 15-valent Human Papillomavirus Vaccine
311	T2	Pruritus due to systemic disorder	Dermatology	5.57	9	2	2	–	7.67	2	HSK21542
312	T2	Vitreoretinal traction syndrome	Rare/Genetic	5.57	9	2	2	–	7.67	2	FIBRINOLYSIN, HUMAN
313	T2	Muscular pain	Infectious Disease	5.56	4.5	1.25	7.76	–	6.46	1	Flarin
314	T2	Arthritis of knee	Immunology & Inflammation	5.56	5	5.07	9.05	–	1.67	4	SOMATROPIN x AUTOLOGOUS PLATELET RICH PLASMA
315	T2	Neuropsychiatric disorders	Rare/Genetic	5.56	8.5	4.55	0	–	5.95	4	SPT-348
316	T2	Locally Advanced Urothelial Carcinoma	Oncology	5.56	5	8.33	2	5.62	4.74	8	PADCEV x KEYTRUDA
317	T2	Cerebral Amyloid Angiopathy, APP-Related	Cardiovascular	5.55	8.5	3.84	0	–	8.25	1	ALZ-1903
318	T2	Carcinoma, Non-Small-Cell Lung	Oncology	5.55	5	6.5	2	8.48	4.52	7	AMIVANTAMAB
319	T2	anaplastic lymphoma kinase	Oncology	5.54	4.5	6.33	8.02	–	1.74	8	CERITINIB
320	T2	Manic state		5.54	5	7.5	2	–	7.23	2	Haloperidol Injection
321	T2	Liver Cancer	Oncology	5.52	4	5.43	10	–	2.49	1	ENB-871
322	T2	Autonomic failure syndrome	Neurology/CNS	5.52	6	3.15	7.01	–	5.95	1	DROXIDOPA
323	T2	Acute Lymphoblastic Leukemia	Oncology	5.51	1	6.56	9.91	10	0	7	NEBRATAMIG
324	T2	Huntington's Disease	Neurology/CNS	5.51	2	6	9.73	7.22	0	79	BEVANTOLOL HYDROCHLORIDE
325	T2	Mycobacterial disease		5.51	7	3.76	4.43	–	5.46	3	RIFABUTIN
326	T2	intellectual disability, autosomal dominant 5	Neurology/CNS	5.51	8.5	4.72	3.18	–	8.25	1	STOKE ASO
327	T2	Immune system disorders		5.51	4.5	5.69	6.15	–	6.27	1	IMMODIN
328	T2	premenstrual syndrome	Cardiovascular	5.51	5	4.38	7.69	–	5.19	1	PROGESTERONE
329	T2	Complication due to and following neuromuscula	Neurology/CNS	5.51	9	2	2	–	7.26	3	SUGAMMADEX x ROCURONIUM BROMIDE
330	T2	Parenteral nutrition-related hepatitis	Infectious Disease	5.51	9	2	2	–	6.82	3	Fish Oil/Glycerol/Egg Lecithin-based Emulsion
331	T2	Rosacea, erythematous telangiectatic type	Oncology	5.51	9	2	2	–	6.51	3	TETRASUL
332	T2	Malignant Peripheral Nerve Sheath Tumor	Oncology	5.5	6	3.94	7.67	–	3.96	1	PAMIPARIB
333	T2	Epileptic encephalopathy with continuous spike	Neurology/CNS	5.5	6	4.32	5.87	–	5.19	1	APINOCALTAMIDE
334	T2	Autism Spectrum Disorder	Psychiatry	5.49	4.5	4.77	9.9	–	1.59	2	GXV-001
335	T2	High grade serous carcinoma	Oncology	5.49	6	3.75	6.38	–	4.71	3	RUCAPARIB CAMSYLATE x NIVOLUMAB
336	T2	Degenerative disorder of muscle		5.48	8	3.85	0.6	–	8.25	1	SIR4156
337	T2	humoral hypercalcemia of malignancy	Oncology	5.48	5	7.5	2	–	6.51	3	DENOSUMAB
338	T2	Vitreoretinal Disorder		5.47	9	0.93	7.04	–	8.25	1	Resolv ER™
339	T2	Papillomavirus Infections	Oncology	5.47	9	3.48	3.65	–	8.25	1	Therapeutic vaccine (cancer, virus) adjuvanted by interleukin-2
340	T2	Severe Acute Respiratory Syndrome	Infectious Disease	5.46	5	3.88	10	10	3.61	1	Zofin
341	T2	Testicular tumour	Oncology	5.46	4.5	4.24	7.71	–	6.46	1	ETOPOSIDE PHOSPHATE
342	T2	Chemotherapy-Induced Thrombocytopenia	Hematology	5.46	5	6	2	10	2.31	23	ROMIPLOSTIM
343	T2	Chronic lymphoid leukemia in relapse	Oncology	5.46	9	2	2	–	6.5	4	Autologous Anti-CD20CAR-CD28-4-1BB-CD3zeta T-lymphocytes MB-106
344	T2	Hyperglycemia due to diabetes mellitus	Metabolic & Endocrine	5.46	9	2	2	–	6.5	4	GLOBALAGLIATIN HYDROCHLORIDE
345	T2	Acute Thymic Involution		5.45	8.5	2	2	–	8.25	1	TBC190
346	T2	Cesium radioisotope		5.45	8.5	2	2	–	8.25	1	NU02 Cesium decorporation
347	T2	Disease [Disease/Finding]	Neurology/CNS	5.45	8.5	2	2	–	8.25	1	Nanoligomer
348	T2	Endocrine, nutritional and metabolic diseases	Metabolic & Endocrine	5.45	8.5	2	2	–	8.25	1	DBL003
349	T2	Fixation device		5.45	8.5	2	2	–	8.25	1	Remote-Controlled Stem Cell Therapy
350	T2	Glucose transporter type 1 deficiency syndrome	Metabolic & Endocrine	5.45	8.5	2	2	–	8.25	1	CBT401
351	T2	Induced psychosis	Psychiatry	5.45	8.5	2	2	–	8.25	1	CSX-5000
352	T2	Insulin-dependent diabetes	Metabolic & Endocrine	5.45	8.5	2	2	–	8.25	1	Encapsulated live cells producing insulin
353	T2	MRSA sinusitis	Infectious Disease	5.45	8.5	2	2	–	8.25	1	OG716
354	T2	Multiple stab wounds		5.45	8.5	2	2	–	8.25	1	DEEPCURE
355	T2	Non-invasive	Oncology	5.45	8.5	2	2	–	8.25	1	Biodegradable Nanoparticles
356	T2	Post-traumatic wound infection		5.45	8.5	2	2	–	8.25	1	OTX PP02
357	T2	Rare genetic disease		5.45	8.5	2	2	–	8.25	1	PASylated enzyme
358	T2	fracture non-union		5.45	8.5	2	2	–	8.25	1	BiG-001 OIF/β-TCP
359	T2	histidyl-tRNA synthetase 1	Rare/Genetic	5.45	8.5	2	2	–	8.25	1	AT_1313
360	T2	laminitis		5.45	8.5	2	2	–	8.25	1	FIDAXOMICIN
361	T2	virus related neoplasm/cancer	Oncology	5.45	8.5	2	2	–	8.25	1	IM-02
362	T2	Acute and chronic respiratory failure	Respiratory	5.44	4.5	3.88	10	–	3.61	1	Ambroxol Hydrochloride
363	T2	Inflammatory conditions of jaw	Immunology & Inflammation	5.44	5	8.57	2	–	2.87	21	DEXAMETHASONE SODIUM PHOSPHATE
364	T2	Post-traumatic pain	Neurology/CNS	5.44	5	8	2	5	5.1	6	Caffetin
365	T2	Infections of kidney	Infectious Disease	5.43	4	4.38	8.17	–	5.68	4	FLOXACILLIN
366	T2	Partial tear	Musculoskeletal	5.43	5	4.08	6.04	–	7.67	1	Trace Orthopedics Tendon Fastener
367	T2	Chronic radiation enteropathy	Gastroenterology	5.42	7	4.61	6.27	–	7.26	1	SYN-020
368	T2	IL-18BP deficiency	Rare/Genetic	5.41	6	5.33	2	–	8.25	1	TADEKINIG ALFA
369	T2	Gastric Disorders	Gastroenterology	5.4	5	4.37	5.5	–	7.23	2	Betacid
370	T2	Primary immune deficiency disorder		5.4	9	2	2	–	5.27	6	HUMAN IMMUNOGLOBULIN G
371	T2	Aortoiliac occlusive disease	Cardiovascular	5.39	9	1.17	6.25	–	8.25	1	GADODIAMIDE
372	T2	Calcific arteriolopathy due to uremia		5.39	7	1.17	5.98	–	7.23	2	HEXASODIUM PHYTATE
373	T2	Acute Duodenal Ulcer with Hemorrhage		5.39	5	6.67	2	–	8.25	1	Lansoprazole injection
374	T2	Allergic diseases	Immunology & Inflammation	5.39	5	6.67	2	–	8.25	1	Diclofenac Sodium Eye Drops
375	T2	Allergic reaction to insect bite	Immunology & Inflammation	5.39	5	6.67	2	–	8.25	1	AFLODERM® Ointment
376	T2	Anemia due to and following chemotherapy	Hematology	5.39	5	6.67	2	–	8.25	1	EPOETIN ALFA
377	T2	Backache, NOS		5.39	5	6.67	2	–	8.25	1	ACECLOFENAC
378	T2	Bite of insect	Dermatology	5.39	5	6.67	2	–	8.25	1	TACT CREAM
379	T2	Chronic gouty arthritis	Immunology & Inflammation	5.39	5	6.67	2	–	8.25	1	FEBUXOSTAT
380	T2	Drug-induced neutropenia	Hematology	5.39	5	6.67	2	–	8.25	1	FILGRASTIM
381	T2	Generalized functional disorder		5.39	5	6.67	2	–	8.25	1	TRIMEBUTINE
382	T2	Infection caused by Clostridium novyi	Infectious Disease	5.39	5	6.67	2	–	8.25	1	Facid
383	T2	Infection caused by beta-hemolytic Streptococc	Infectious Disease	5.39	5	6.67	2	–	8.25	1	Facid
384	T2	Inflammatory disorder of musculoskeletal syste	Immunology & Inflammation	5.39	5	6.67	2	–	8.25	1	BENZYDAMINE
385	T2	Injury of external auditory canal	Immunology & Inflammation	5.39	5	6.67	2	–	8.25	1	CIPROFLOXACIN
386	T2	Intestinal infectious disease caused by anaero	Infectious Disease	5.39	5	6.67	2	–	8.25	1	Zydotum
387	T2	Lower limb ischemia		5.39	5	6.67	2	–	8.25	1	Neovasculgen
388	T2	Neonatal aspiration syndromes	Rare/Genetic	5.39	5	6.67	2	–	8.25	1	Omeprazole Sodium for Injection
389	T2	Oral Cavity and Lip Precancerous Condition	Oncology	5.39	5	6.67	2	–	8.25	1	Straticyte
390	T2	Post-surgery back pain		5.39	5	6.67	2	–	8.25	1	Flamar MX
391	T2	Recurrent manic episodes	Psychiatry	5.39	5	6.67	2	–	9.01	1	Milsaperidone (Bysanti)
392	T2	Transfusion-transmitted infectious disease	Infectious Disease	5.39	5	6.67	2	–	8.25	1	Transfusion-transmitted Virus (TTV) Real Time PCR Kit
393	T2	Renal injury	Nephrology/Urology	5.38	5	3.71	10	–	2.11	1	Exonox Renal ELISA
394	T2	Bone loss	Musculoskeletal	5.38	5	3.33	6.42	–	8.25	1	DENOSUMAB
395	T2	Corneal endothelial disorder	Ophthalmology	5.37	4.5	3.89	7.76	–	5.27	6	ZH906
396	T2	Non-Proliferative Diabetic Retinopathy	Cardiovascular	5.37	6	3.12	7.15	–	4.25	2	TTAX01
397	T2	Acute dermatitis	Dermatology	5.37	5	4.65	4.99	–	7.67	1	Septomida MD Spray
398	T2	Allergic disorder of skin	Infectious Disease	5.37	5	4.42	5.31	–	7.67	1	Histamine Human Immunoglobulin
399	T2	Metastasis to bone	Oncology	5.36	4	5	8.4	–	4.58	1	SHR-2017
400	T2	Periapical disease	Infectious Disease	5.35	5	3.75	5.7	–	8.25	1	Cresatin
401	T2	Recurrent Fallopian Tube High Grade Serous Ade	Oncology	5.35	9	2	2	–	6.1	8	Anti-VEGF Monoclonal Antibody x BEVACIZUMAB x CARBOPLATIN x GEMCITABINE x Pegylated Liposomal Doxorubicin Hydrochloride
402	T2	Recurrent Ovarian High Grade Serous Adenocarci	Oncology	5.35	9	2	2	–	6.1	8	Anti-VEGF Monoclonal Antibody x BEVACIZUMAB x CARBOPLATIN x GEMCITABINE x Pegylated Liposomal Doxorubicin Hydrochloride
403	T2	Recurrent Primary Peritoneal High Grade Serous	Oncology	5.35	9	2	2	–	6.1	8	Anti-VEGF Monoclonal Antibody x BEVACIZUMAB x CARBOPLATIN x GEMCITABINE x Pegylated Liposomal Doxorubicin Hydrochloride
404	T2	Sanfilippo Syndrome	Metabolic & Endocrine	5.34	8.5	1.68	4.23	–	8.25	1	ALL-027
405	T2	Arthritis, Rheumatoid	Immunology & Inflammation	5.34	9	2.17	4.61	–	8.25	1	Djit PIP
406	T2	Respiratory infections, chronic recurrent	Infectious Disease	5.34	9	2.67	0	–	7.67	2	RSP-1502
407	T2	Moderate risk of	Cardiovascular	5.34	5	6.67	2	5	8.25	1	OLEZARSEN
408	T2	Neurogenic Inflammation	Gastroenterology	5.34	9	0	3.16	–	8.25	1	CoolStat
409	T2	hemolytic disease of the fetus	Hematology	5.34	5	6.5	2	–	7.81	1	NIPOCALIMAB
410	T2	Idiopathic bronchiectasis	Infectious Disease	5.33	5	3.56	4.56	–	7.23	2	Cefaclor Sustained-release Capsules
411	T2	Ornithine transcarbamylase deficiency	Neurology/CNS	5.33	5	4.08	6.14	–	7.26	1	GTP-506
412	T2	Skeletal defects		5.33	7	5.15	0	–	8.25	1	Autologous Multipotent Mesenchymal Stem Cells
413	T2	Atherosclerotic occlusive disease	Cardiovascular	5.32	9	1.17	6.25	–	7.67	2	LERODALCIBEP
414	T2	Metastatic malignant neoplasm to liver	Oncology	5.32	3.5	5.61	10	–	1.1	6	TLR7 Agonist RO7119929 x TOCILIZUMAB
415	T2	Restriction		5.32	5	3.1	9.2	–	4.07	2	VibraCool
416	T2	Spasms	Women's & Reproductive Health	5.32	3.5	5.95	7.57	–	5.03	1	DROTAVERINE
417	T2	Edematous fibrosclerotic panniculopathy		5.32	6	5.6	2	5.15	6.82	3	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
418	T2	Lung diseases due to external agents	Respiratory	5.32	8.5	2	2	–	6.51	3	LM007
419	T2	Amyloid light-chain amyloidosis	Oncology	5.31	4	3.92	9.96	–	3.48	4	DARATUMUMAB
420	T2	Primary hypertension	Cardiovascular	5.31	4	5.1	7.68	–	4.82	3	DOXAZOSIN MESYLATE
421	T2	Cushing's syndrome	Psychiatry	5.31	3	5.71	8.56	–	5.37	1	RELACORILANT
422	T2	Hesitation wounds		5.31	5	6.67	2	–	7.23	2	InnovaMatrix® PD
423	T2	Hyperphenylalaninemia, non-phenylketonuric		5.31	5	6.67	2	–	7.23	2	SAPROPTERIN DIHYDROCHLORIDE
424	T2	Malignant melanoma with BRAF V600E mutation	Oncology	5.31	5	6.67	2	–	7.23	2	ENCORAFENIB
425	T2	Other functional intestinal disorders	Gastroenterology	5.31	5	6.67	2	–	7.23	2	ACTAPULGITE
426	T2	Ligament Injury		5.3	3	5	9.11	–	3.36	1	CRMA®
427	T2	Spinal Cord Injury	Neurology/CNS	5.3	3	5	9.11	–	3.36	1	MyndMove
428	T2	Traumatic injury		5.3	3	5	9.11	–	3.36	1	ABCcolla® Bone Graft
429	T2	Clear cell endometrial carcinoma	Oncology	5.3	4.5	4.86	9.49	–	1.37	1	ADU-1805
430	T2	Severe coagulase-negative Staphylococcus infec	Infectious Disease	5.3	5	2.44	7.18	–	8.25	1	Cefazedone Sodium for Injection
431	T2	Exocrine pancreatic dysfunction	Gastroenterology	5.29	4	4.22	7.85	–	6.46	1	SECRETIN SYNTHETIC HUMAN
432	T2	Intervertebral Disc Displacement		5.29	5	3.42	8	–	5.03	1	ZLift
433	T2	Mild neurocognitive disorder	Neurology/CNS	5.28	6	2.5	6.87	–	5.69	1	Fish Oil/Glycerol/Egg Lecithin-based Emulsion
434	T2	Cervical syndrome	Rare/Genetic	5.28	5	4.17	6.66	–	5.47	1	Bals Sulphur Gel
435	T2	Acute disease of musculoskeletal system	Musculoskeletal	5.27	5	5.95	3.06	–	6.51	3	CYCLOBENZAPRINE HYDROCHLORIDE
436	T2	Dementia due to cobalamin deficiency	Neurology/CNS	5.27	4	4.51	8.07	–	5.37	1	MECOBALAMIN
437	T2	Juvenile psoriatic arthritis with psoriasis	Immunology & Inflammation	5.27	5	5.63	4.59	–	4.82	3	ETANERCEPT
438	T2	hemolytic disease		5.26	4.5	4.29	7.16	–	6.1	1	total bilirubin assay kit
439	T2	Acute respiratory disease	Respiratory	5.26	4.5	3.21	10	–	2.86	2	SuiShotⓇ TR
440	T2	Fracture repair	Musculoskeletal	5.26	6	2.29	6.67	–	6.27	1	OsteoAdapt SP
441	T2	Coenzyme Q deficiency		5.26	8	2	2	–	8.25	1	UBIDECARENONE
442	T2	Injury of soft tissue of face		5.26	8	2	2	–	8.25	1	A3T01
443	T2	Peripheral Artery Disease		5.25	4	4.73	9.54	–	2.59	1	MOTIV Bioresorbable Scaffold
444	T2	Psychoactive substance use disorder, NOS	Psychiatry	5.25	5	6.67	2	–	6.82	3	NarcoStem
445	T2	Transthyretin-mediated amyloidosis	Cardiovascular	5.25	5	6.67	2	–	6.51	3	VUTRISIRAN
446	T2	Non-Malignant	Oncology	5.24	6	5	2	–	7.67	2	UM171 Cell Therapy
447	T2	T-cell AND/OR NK-cell neoplasm	Oncology	5.24	7	3.33	2	–	9.01	1	GENOLIMZUMAB
448	T2	Amyloid polyneuropathy type I	Rare/Genetic	5.22	5	6.67	2	5	6.82	3	EPLONTERSEN
449	T2	Cystic disease of liver	Gastroenterology	5.21	5	5.17	4.86	–	5.95	1	ALBENDAZOLE
450	T2	Vaginal Neoplasms	Oncology	5.21	5	3.33	5.56	–	8.25	1	SPORLAC PLUS
451	T2	benign vaginal mixed tumor	Oncology	5.21	5	3.33	5.56	–	8.25	1	Povidone Iodine Vaginal Effervescent Tablets
452	T2	Chronic ischaemic heart disease	Cardiovascular	5.21	5	6.67	2	–	5.75	4	MT-102
453	T2	Purpura	Immunology & Inflammation	5.2	5	3.04	7.47	–	5.95	1	PlasmaGlob
454	T2	Post-traumatic neuralgia	Nephrology/Urology	5.2	4.5	5	7.38	–	3.09	2	AP707
455	T2	Rheumatism		5.2	5	4.46	4.04	–	8.25	1	ACECLOFENAC
456	T2	Anogenital candidiasis	Oncology	5.2	5	6.2	2	7.5	3.67	18	TSC-203-A0201
457	T2	Open injury		5.19	4.5	3.71	10	–	2.11	1	Yunnan Baiyao Woundplast
458	T2	Necrotic tumor		5.19	4.5	2.92	7.78	5	7.26	1	Flaminal Hydro
459	T2	Carcinoma of ureter	Oncology	5.18	6	2.5	7.22	–	4.69	5	Docetaxel x Icrucumab
460	T2	gastroesophageal adenocarcinoma	Oncology	5.18	4	6.79	7.11	5	1.36	2	KEYTRUDA x LENVIMA
461	T2	Acquired fibrinogen deficiency		5.18	4.5	4.12	6.96	–	5.81	1	FIBRINOGEN, HUMAN
462	T2	Postoperative Pain		5.18	6	5	2	–	6.51	3	ROPIVACAINE
463	T2	Secondary malignant neoplasm of lung	Oncology	5.18	9	2	2	–	4.13	20	PEMETREXED
464	T2	Amyloid angiopathy	Cardiovascular	5.17	6	3.66	7.92	–	7.26	1	RESAMIRIGENE BILPARVOVEC
465	T2	Retinal Vascular Disorder	Cardiovascular	5.17	1.5	7.04	9.21	–	4.44	2	UBX2048
466	T2	Knee Injury		5.17	5	2.41	7.01	–	7.67	1	gMSC®1
467	T2	Epilepsy	Neurology/CNS	5.16	1	8.45	10	–	2.24	1	OneRF System
468	T2	Perianal fistula due to Crohn's disease	Immunology & Inflammation	5.16	7	3.33	2	–	7.23	2	AVB-114
469	T2	Spinal cord disease	Neurology/CNS	5.15	4	3.99	6.64	–	7.67	1	BAROPAN
470	T2	Infectious disorder of kidney	Infectious Disease	5.15	5	2.5	7.6	–	6.46	1	Cefoperazone for Injection
471	T2	Liver Fibrosis	Infectious Disease	5.14	2.5	5.63	9	–	1.48	5	Fuzheng Huayu Capsule
472	T2	Corneal Diseases	Ophthalmology	5.14	6	3.15	4.93	–	6.27	1	3DBT corneas
473	T2	Macular neovascularization	Cardiovascular	5.14	6	3.15	4.93	–	6.27	2	4D-150
474	T2	fallopian tube cancer	Oncology	5.13	4.5	6.44	6.68	–	0.65	3	PAMIPARIB
475	T2	Primary malignant neoplasm of liver	Oncology	5.13	3	5.61	10	–	2.1	2	CHEMOSAT Hepatic Delivery System
476	T2	Vena Cava	Cardiovascular	5.13	5	2.08	6.84	–	8.25	1	sinus-XL
477	T2	Sluggishness	Gastroenterology	5.12	5	2.72	7.16	–	6.46	3	Eucarbon® nutrition
478	T2	Hearing Loss, Hidden		5.11	7	3.33	2	–	6.27	3	CIL001
479	T2	MET mutation-related tumors	Oncology	5.11	7	4	2	–	4.44	9	AB-001
480	T2	Low Grade Glioma	Oncology	5.1	4	5.41	7.25	–	3.61	1	BDTX-1535
481	T2	Primary Systemic Amyloidosis	Metabolic & Endocrine	5.09	4.5	2.25	9.96	–	3.72	3	FCN-338
482	T2	Pain inflammation activated	Immunology & Inflammation	5.09	9	4.53	0	–	8.25	1	GSK1482160
483	T2	Prohormone Convertase 1 Deficiency	Rare/Genetic	5.08	9	4.53	0.6	–	6.51	3	SETMELANOTIDE
484	T2	upper digestive tract disorder	Gastroenterology	5.08	5	3.28	5.03	–	8.25	1	EvoEndo® System
485	T2	Bone and joint infection	Infectious Disease	5.08	1	6.72	10	–	5.11	1	Cefazolin Sodium for Injection
486	T2	Apoplexy	Cardiovascular	5.08	5	2.08	6.6	–	8.25	1	Yizhi Kangnao
487	T2	Calcific tendinitis		5.08	6	1.17	5.98	–	8.25	1	Pulse IVL System
488	T2	Hepatic carcinoma malignant primary recurrent	Oncology	5.08	8	2	2	–	5.95	4	Huaier Extract Granule
489	T2	Interstitial lung fibrosis	Respiratory	5.07	3	4.6	9	–	2.23	1	Bovhyaluronidase azoximer
490	T2	Fatigue due to and following ischemic cerebrov	Cardiovascular	5.07	2.5	6.36	10	–	1.55	1	BP1.3656
491	T2	Mucocutaneous ulcer	Infectious Disease	5.07	5	2.92	6.66	–	6.46	1	INTERFERON ALFA
492	T2	Moderate manic bipolar I disorder	Psychiatry	5.07	5	6.67	2	–	4.95	9	LUMATEPERONE
493	T2	Bacterial infection of skin	Infectious Disease	5.06	2.5	6.25	8.13	–	4.47	1	Levofloxacin Bluefish
494	T2	Mitochondrial metabolism defect	Rare/Genetic	5.05	3	6.49	6.69	–	4.75	1	ELAMIPRETIDE
495	T2	Bone Infections	Infectious Disease	5.05	5	4.15	5.84	5	2.72	17	CIPROFLOXACIN
496	T2	Chemotherapy induced neutropenia	Hematology	5.05	5	7.38	2	5.5	0.6	43	PEGFILGRASTIM
497	T2	Recurrent non-tuberculous mycobacterial infect	Infectious Disease	5.05	5	3.33	2	9	7.23	2	DELPAZOLID
498	T2	Adult T-Cell Leukemia/Lymphoma	Oncology	5.04	4.5	4.17	7.74	–	3.53	1	VALEMETOSTAT
499	T2	Fontan-associated liver disease	Immunology & Inflammation	5.04	8.5	2	2	–	8.25	1	EVerGel
500	T2	Chronic Pseudomonas aeruginosa infection	Infectious Disease	5.03	8	1.67	0	–	6.51	3	OMN-51
501	T2	Cervical Vertebra	Women's & Reproductive Health	5.03	5	4.09	4.9	–	6.02	2	Thermal Therapy Plaster
502	T2	Renal neoplasms	Oncology	5.03	7	4.06	0	–	8.25	1	ARCHEXIN
503	T2	blood group incompatibility		5.03	9	1.25	0	–	8.25	1	RA02A x RA02B
504	T2	Locally advanced breast cancer	Oncology	5.02	4.5	3.86	9.49	–	2.12	1	177Lu-BetaBart; BetaBart; RV-01
505	T2	Candidal infections	Infectious Disease	5.02	5	5.33	2	–	8.25	1	FLUCONAZOLE
506	T2	Methicillin-Sensitive Staphylococcus aureus In	Infectious Disease	5.02	7	2.5	2	–	8.25	1	CTI-005
507	T2	Autosomal Recessive Hypophosphatemia Rickets	Musculoskeletal	5.01	8	2.29	4.4	–	8.25	1	INZ-701
508	T2	Head and neck cancer	Oncology	5.01	1	5.9	10	10	0.49	1	Enoblituzumab; MGA271
509	T2	Recurrent Malignant Glioma	Oncology	5.01	3.5	5.71	8.69	5	2.34	1	MT027 cells suspension; MT027 CAR-T cells; MT027 UCAR-T
510	T2	Progressive volume loss		5.01	3.5	4.32	7.3	–	5.71	3	STYLAGE®
511	T3	Escherichia coli Infections	Infectious Disease	5.01	4	2.89	8.11	–	5.93	3	Cefalexin Tablets
512	T3	Staphylococcus infection	Infectious Disease	5.0	4.5	2.9	7.85	–	4.58	5	Acetylspiramycin Tablets
513	T3	Spinal tumors	Oncology	4.99	5	2.5	5.62	–	8.25	1	BlackArmor® Carbon/PEEK Anterior Cervical Plate
514	T3	Chronic intestinal failure	Infectious Disease	4.98	2	4.33	10	–	3.29	1	CR-13/01
515	T3	Marburg disease		4.98	8	1.67	5.74	–	6.51	3	GALIDESIVIR
516	T3	Diarrhea post chemotherapy	Oncology	4.98	1	5.75	10	10	0	1	CROFELEMER
517	T3	disease of the blood	Infectious Disease	4.98	1	7.24	9.52	–	4.03	1	AMIKACIN
518	T3	Squamous Intraepithelial Lesions	Oncology	4.98	5	2.45	8.48	–	3.96	1	Papilocare
519	T3	ACTH Syndrome, Ectopic	Rare/Genetic	4.98	6	1.25	5.75	–	7.67	1	OSILODROSTAT
520	T3	GLUT1 Deficiency Syndrome 1	Metabolic & Endocrine	4.97	6	2.06	4.19	–	8.25	1	TRIHEPTANOIN
521	T3	Acute respiratory infections	Infectious Disease	4.97	1.5	5.38	9.86	–	5.81	1	NP-339
522	T3	fertility disorders		4.97	5	6.67	2	–	3.44	16	FOLLITROPIN DELTA x Human Menopausal Gonadotropin
523	T3	Cholangiocarcinoma		4.94	3	5.46	9.18	–	2.11	1	INFIGRATINIB
524	T3	Light chain disease	Oncology	4.94	4.5	4.58	9.96	0	4.03	2	IPH6401 SAR514
525	T3	Bile Ducts	Infectious Disease	4.94	5	3.11	7.16	–	4.33	1	Cefazolin Sodium for Injection
526	T3	Retinal angiopathy	Cardiovascular	4.93	5	3.99	7.92	–	7.26	1	Acid yellow 73 sodium salt
527	T3	Intestinal infections due to other organisms	Infectious Disease	4.93	5	5	2	–	8.25	1	Vabomere
528	T3	Systemic Juvenile Idiopathic Arthritis	Immunology & Inflammation	4.92	1	5.67	8.57	–	3.56	1	ANAKINRA
529	T3	complement 3 glomerulopathy	Nephrology/Urology	4.92	4.5	4.02	6.25	6.67	4.59	7	PEGCETACOPLAN
530	T3	shock syndrome	Rare/Genetic	4.92	3	5.83	8.51	–	2.35	1	Dopamine Hydrochloride Injection
531	T3	IgE-mediated allergic disorder	Immunology & Inflammation	4.92	5	2.75	5.31	–	7.67	1	Kenota 1 Total IgE test system
532	T3	respiratory disease	Respiratory	4.91	1	6.67	10	–	3.52	3	Madame Pearl's Cough Syrup
533	T3	End-stage renal disease	Nephrology/Urology	4.9	4.5	2.67	9.97	–	2.11	1	CSL525
534	T3	degenerative brain disease		4.9	8.5	1.03	0.6	–	8.25	1	Gene-cell therapy for Degenerative (brain) diseases
535	T3	Vasomotor rhinitis	Women's & Reproductive Health	4.9	3.5	5.14	5.66	–	6.46	1	ELINZANETANT
536	T3	HPV infection	Oncology	4.89	8.5	1.43	0	–	8.25	1	NTX-250
537	T3	Intrabony periodontal defect	Infectious Disease	4.88	7	2	2	–	8.25	1	MD05
538	T3	Neurotrophic keratoconjunctivitis	Neurology/CNS	4.88	7	2	2	–	8.25	1	NRO-1
539	T3	Non-small cell adenocarcinoma of lung	Respiratory	4.88	7	2	2	–	8.25	1	2,2'-DITHIODIETHANESULFONIC ACID
540	T3	Orolabial HSV infections		4.88	7	2	2	–	8.25	1	HDIT101
541	T3	Paralysis due to lesion of spinal cord	Neurology/CNS	4.88	7	2	2	–	8.25	1	ExaStim
542	T3	Reduced ejection fraction co-occurrent and due	Cardiovascular	4.88	7	2	2	–	8.25	1	BC-007
543	T3	prostate cancer prevention	Oncology	4.88	7	2	2	–	8.25	1	Theakine® Prost
544	T3	synaptopathy	Neurology/CNS	4.88	7	2	2	–	8.25	1	CIL001
545	T3	Malignant epithelial tumor	Oncology	4.87	5	5.58	5.33	–	0.24	5	BCN077
546	T3	Salmonella infection	Infectious Disease	4.87	4.5	1.62	8.17	–	6.24	1	GSK4077164
547	T3	Epidermitis		4.86	6	3.33	2	–	8.25	1	NJ-09-EE
548	T3	Osteomyelitis caused by Staphylococcus aureus	Metabolic & Endocrine	4.86	6	3.33	2	–	8.25	1	BX211
549	T3	Chylomicronemia syndrome	Metabolic & Endocrine	4.85	5	4.21	5.57	–	6.68	4	PRADIGASTAT x FENOFIBRATE x PRADIGASTAT x Fish Oil Capsules
550	T3	Hereditary angioedema with C1 esterase inhibit	Immunology & Inflammation	4.85	7	3.28	4.03	–	8.25	1	BMN-331
551	T3	Eye injury	Ophthalmology	4.85	3.5	4.41	8.85	–	2.77	1	iNexin
552	T3	Cataracts, infantile	Ophthalmology	4.84	9	3.75	0	–	7.67	2	SVT-15473
553	T3	Condyloma acuminatum of the anogenital region	Infectious Disease	4.84	4	3.3	7.8	5	4.44	2	Tsegardex
554	T3	pulmonary non-tuberculous mycobacterial infect	Respiratory	4.83	6	2.19	4.43	–	6.46	1	ARINA-1
555	T3	Endometrial cancer	Oncology	4.83	4	3.86	9.49	–	1.37	1	DOSTARLIMAB
556	T3	Lumbar Vertebra		4.83	5	2.08	7.54	–	5.03	1	Thermal Therapy Plaster
557	T3	Thoracic pain		4.83	5	2.08	7.54	–	5.03	1	Biolevox Neuro
558	T3	Neuroendocrine Tumors	Oncology	4.82	1	6.32	9.08	–	1.66	10	VOROLANIB
559	T3	Fallopian tube cancer	Oncology	4.82	4	5.77	6.68	–	2.16	1	BEVACIZUMAB
560	T3	Cryptococcal infections	Neurology/CNS	4.82	4	3.33	7.52	–	5.27	1	MAT2203
561	T3	Adrenal tumors	Oncology	4.81	5	3.31	8.51	–	3.7	1	TIGOZERTINIB
562	T3	Paralysis, Infantile		4.8	5	3.98	2.72	–	8.25	1	Aceglutamide for Injection
563	T3	Scars	Psychiatry	4.8	7	2	2	–	7.23	2	Autologous Fibroblast Transplantation
564	T3	Advanced Hepatocellular Carcinoma	Oncology	4.79	1	6.36	10	–	1.15	1	CAR (hYP7)-T cells
565	T3	Hepatocellular Carcinoma	Oncology	4.79	1	6.36	10	–	0.4	1	IPILIMUMAB
566	T3	Chronic Lymphocytic Leukemia	Oncology	4.79	1	6.54	9.44	–	0	5	EPOETIN ALFA
567	T3	Nystagmus, infantile		4.79	9	0.38	0	–	8.25	1	NERAMEXANE MESYLATE
568	T3	Pancreatic Adenocarcinoma	Gastroenterology	4.79	4.5	1.77	7.85	–	5.83	7	Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A x PEMBROLIZUMAB x CISPLATIN x CARBOPLATIN
569	T3	Deep third degree burn injury		4.78	6	3.33	2	–	7.67	2	Recombinant Human Acidic Fibroblast Growth Factor For External Use
570	T3	feline leukemia virus infection	Oncology	4.77	1	6.34	10	–	0	2	Speed Duo FeLV/FIV
571	T3	Urothelial Carcinoma	Oncology	4.77	1	6.36	8.62	8	0	145	FUTIBATINIB
572	T3	Female genital tract infection	Infectious Disease	4.77	5	2.5	4.54	–	7.81	1	CEFTAZIDIME
573	T3	Progressive WHO Grade 4 Glioma	Oncology	4.76	4	4.16	7.25	–	3.61	1	TVI-Brain-1
574	T3	liver diseases	Gastroenterology	4.76	4	4.5	5.81	–	4.35	3	Dualase
575	T3	Allergic conditions	Immunology & Inflammation	4.76	5	2.17	5.31	–	7.67	1	CHLORPHENOXAMINE
576	T3	ATTR Amyloidosis	Neurology/CNS	4.75	1.5	5.51	6.71	–	4.83	2	Coramitug
577	T3	Transthyretin related familial amyloid cardiom	Cardiovascular	4.75	1.5	5.51	6.71	–	4.83	3	NTLA-2001
578	T3	transthyretin amyloidosis	Cardiovascular	4.75	1.5	5.51	6.71	–	4.52	3	INOTERSEN
579	T3	Radiation esophagitis	Oncology	4.75	1.5	6.75	10	–	1.26	1	Avasopasem Manganese x GC4419
580	T3	Membranoproliferative Glomerulonephritis	Nephrology/Urology	4.75	5	2.6	4.7	–	7.67	1	IPTACOPAN
581	T3	Metastatic malignant neoplasm	Oncology	4.74	2	6.01	9.8	–	1.1	3	MASL
582	T3	Subcutaneous tumor	Oncology	4.74	5	1.98	5.11	–	8.25	1	PetXmark
583	T3	Venous ulcer of leg		4.74	4	3.12	7.39	5	5.03	1	Venucreme
584	T3	respiratory tract disease	Respiratory	4.73	1	6.26	9.86	–	0.87	47	Quadri-subtype Influenza VLP Vaccine
585	T3	Infection caused by anaerobic bacteria	Infectious Disease	4.73	4.5	2.71	5.01	–	8.25	1	GENTAMICIN SULFATE
586	T3	Advanced Head and Neck Squamous Cell Carcinoma	Oncology	4.71	3	5.25	9.46	–	0.57	1	EMUNKITUG
587	T3	Bone loss in jaw	Oncology	4.71	5	5.68	0	–	8.25	1	DENOSUMAB
588	T3	Diffuse midline glioma H3K27M mutation	Oncology	4.71	7	3	0	5	7.23	2	DORDAVIPRONE
589	T3	Head and Neck Carcinoma	Oncology	4.69	3	5.16	9.46	–	0.13	5	IM-1021 x IM-3050 x IMM-ONC-01 x AL102 (varegacestat) x IM-1617 x IM-1335 x IM-1340
590	T3	Lip Neoplasms	Oncology	4.69	5	3.03	4.5	–	5.93	5	NIO® Laser Imaging System
591	T3	Diffuse midline glioma, point mutation K27M in	Oncology	4.69	9	0	0	–	8.25	1	H3K27M Long Peptide Vaccine
592	T3	Immune dysfunction		4.68	1	6.39	10	–	2.39	1	ICLAPRIM
593	T3	Osteoblastic Metastatic Bone Lesion	Oncology	4.68	5	2.17	4.52	–	8.25	1	Samarium [153Sm] Lexidronam Injection
594	T3	Acute myeloid leukemia	Oncology	4.67	1	6.04	9.44	–	0.38	3	ETOPOSIDE PHOSPHATE
595	T3	Cytomegalovirus infection	Infectious Disease	4.65	3.5	2.78	9.02	–	3.57	2	LETERMOVIR
596	T3	thrombotic disease		4.65	1	7.11	8.26	5.41	0	29	ASPIRIN
597	T3	Optic Nerve Diseases	Neurology/CNS	4.65	3.5	3.5	8.29	–	3.96	1	NPX461
598	T3	Type II diabetes	Metabolic & Endocrine	4.64	1	7.55	10	–	0	5	Sublingual Insulin
599	T3	periprosthetic joint infection	Infectious Disease	4.64	5	5	2	–	4.91	8	PLG-0206
600	T3	Vaso-occlusive pain episode in sickle cell dis		4.63	2	4.03	9.24	–	1.51	4	INCLACUMAB
601	T3	Coronary arteriosclerosis	Cardiovascular	4.63	1	6.95	10	–	1.33	1	SIMVASTATIN
602	T3	blood coagulation disorders		4.63	1	5.76	9.52	5	1.92	14	Human Prothrombin Complex
603	T3	Resistant hypertension	Cardiovascular	4.62	1	6.1	10	–	1.96	2	Aldosterone Synthase Inhibitor
604	T3	indolent lymphoma	Oncology	4.61	1	5.81	9.67	–	0	10	KPG-818
605	T3	CKD	Metabolic & Endocrine	4.61	1	6.44	10	–	2.94	1	MW-401
606	T3	Obesity Management	Metabolic & Endocrine	4.61	1	6.44	10	–	2.94	1	PEMVIDUTIDE
607	T3	Obesity-Related Malignant Neoplasm	Metabolic & Endocrine	4.61	1	6.44	10	–	2.19	1	ABC-294640
608	T3	Ewing sarcoma / peripheral neuroectodermal tum	Oncology	4.61	7	0.42	5.35	–	4.47	1	CIXUTUMUMAB
609	T3	chronic actinic dermatitis	Dermatology	4.6	5	2	2	–	8.25	1	Fendactin
610	T3	Primary Peritoneal Cancer	Oncology	4.6	5	4.17	6.12	–	1.32	1	AVB-001
611	T3	Breast Carcinoma	Oncology	4.59	1	5.87	10	–	3.2	1	PERTUZUMAB
612	T3	Strain - lesion		4.59	5	4	2	5	6.51	3	Venucreme
613	T3	Small cell lung cancer metastatic	Oncology	4.58	1	5.6	9.5	–	0.78	1	SYS6043
614	T3	Ornithine transcarbamylase deficiency	Metabolic & Endocrine	4.58	4.5	1.5	6.14	–	7.26	1	SODIUM PHENYLBUTYRATE
615	T3	Nutritional supplement		4.58	5	5.21	0	–	8.25	1	Superchic
616	T3	Systemic infections	Infectious Disease	4.57	4	1.25	8.17	–	6.68	1	Cefazolin Sodium for Injection
617	T3	lung tumor	Oncology	4.56	1	6.75	10	–	0.5	7	Bronchoscope-guided Electrode
618	T3	Streptococcus infection	Infectious Disease	4.56	3	3.12	7.86	–	5.35	4	Acetylspiramycin Tablets
619	T3	Cerebral vascular lesion	Cardiovascular	4.55	5	2.42	3.56	–	8.25	1	Other TCM Patent Medicines
620	T3	Cancer anemia	Oncology	4.53	1	6.29	10	–	1.96	1	AND017
621	T3	Chronic hyperglycaemia	Metabolic & Endocrine	4.52	1	7.11	10	–	0.79	1	TW68
622	T3	Pelvic Inflammatory Disease	Infectious Disease	4.52	3	2.96	8.49	–	5.19	1	Cefoxitin Sodium for Injection
623	T3	Pleura carcinoma	Oncology	4.51	2.5	4.5	10	–	1.18	1	MT027
624	T3	Carcinoma squamous	Oncology	4.51	1.5	5.15	10	–	2.63	1	IM-1021 x IM-3050 x IMM-ONC-01 x AL102 (varegacestat) x IM-1617 x IM-1335 x IM-1340
625	T3	Fungal infections	Infectious Disease	4.51	1	5.61	9.86	–	3.33	1	CASPOFUNGIN ACETATE
626	T3	Gram-Negative Bacterial Infections	Infectious Disease	4.51	1.5	5.81	7.45	–	5.19	1	BAL2420
627	T3	Chronic Obstructive Pulmonary Disease	Gastroenterology	4.5	1	6.68	10	–	0.94	1	Gamma glutamyl transferase assay kit
628	T3	Malignant epithelial neoplasm	Oncology	4.49	5	3.91	5.33	–	1.44	1	121Pb
629	T3	Breast cancer	Oncology	4.49	1	7	10	–	0	1	ELINZANETANT
630	T3	Rheumatoid Arthritis	Immunology & Inflammation	4.49	1	6.87	10	–	0.46	2	METHOTREXATE
631	T3	arthritis pain	Immunology & Inflammation	4.49	1	6.87	10	–	0	3	YJF-015
632	T3	Clark melanoma level 1	Oncology	4.49	6	2	2	–	8.25	1	BS-001
633	T3	Osteochondral injury		4.49	6	2	2	–	8.25	1	Agili-C
634	T3	Paediatric acute-onset neuropsychiatric syndro	Neurology/CNS	4.49	6	2	2	–	8.25	1	NTI164
635	T3	Pain, Postoperative	Immunology & Inflammation	4.49	6	2	2	–	8.25	1	TEV-'749
636	T3	Neurologic involvement	Cardiovascular	4.48	5	4.83	0	–	8.25	1	METHYLPREDNISOLONE
637	T3	Infection caused by Pseudomonas aeruginosa	Infectious Disease	4.48	6	3.96	0	–	7.26	1	DXR inhibitor program
638	T3	Parenteral Nutrition	Infectious Disease	4.48	5	3.48	1.81	–	8.25	1	NutriLock
639	T3	5,10-Methylenetetrahydrofolate reductase		4.48	5	3.33	2	–	8.25	1	BETAINE
640	T3	Brain Injury, Chronic	Cardiovascular	4.48	5	3.33	2	–	8.25	1	CHOLINE ALFOSCERATE
641	T3	Caprine arthritis-encephalitis	Neurology/CNS	4.48	5	3.33	2	–	8.25	1	Small Ruminant Lentivirus Antibody Test Kit, cELISA
642	T3	Chronic bronchial disease	Immunology & Inflammation	4.48	5	3.33	2	–	8.25	1	Hedecid Syrup
643	T3	Correction		4.48	5	3.33	2	–	8.25	1	STYLAGE®
644	T3	Genitourinary tract infection	Infectious Disease	4.48	5	3.33	2	–	8.25	1	CELEX-250
645	T3	Infection by Oesophagostomum	Infectious Disease	4.48	5	3.33	2	–	8.25	1	ASHITAL 5% Injection
646	T3	Infection by Strongyloides	Infectious Disease	4.48	5	3.33	2	–	8.25	1	ASHITAL 5% Injection
647	T3	Infection in the elderly	Infectious Disease	4.48	5	3.33	2	–	8.25	1	Heartworm Antigen Test Kit
648	T3	MSI-H Colorectal Carcinoma	Oncology	4.48	5	3.33	2	–	9.01	1	PEMBROLIZUMAB
649	T3	Mood disorder with manic symptoms caused by hy	Gastroenterology	4.48	5	3.33	2	–	8.25	1	A Tai Ning
650	T3	Parasitosis	Psychiatry	4.48	5	3.33	2	–	8.25	1	AQUACEN FORMALDEHYDE
651	T3	Primary herpes simplex infection of lips	Infectious Disease	4.48	5	3.33	2	–	8.25	1	Lipovir
652	T3	envenomation		4.48	5	3.33	2	–	8.25	1	Antitoxin for poison of European snake
653	T3	gallstone disease		4.48	5	3.33	2	–	8.25	1	Ursovef
654	T3	Urinary infection	Infectious Disease	4.47	1	5.76	10	–	2.56	1	NORFLOXACIN
655	T3	Negative symptoms in schizophrenia	Psychiatry	4.45	1	6.53	10	–	0.42	4	HBL20030
656	T3	Biliary disorders	Gastroenterology	4.45	5	2.08	3.56	–	8.25	1	Hydroxybutyloxide
657	T3	Vasomotor disturbance		4.45	4	2.79	5.66	–	6.46	1	GS1-144
658	T3	Venous malformations	Cardiovascular	4.44	6	3.81	0	8.75	7.26	3	QTORIN™ rapamycin
659	T3	Diffuse low grade B-cell lymphoma	Oncology	4.43	1	4.62	9.29	5	0.3	3	FS118
660	T3	neck syndrome	Rare/Genetic	4.43	1.5	5.59	9.8	–	1.54	1	LOXOPROFEN
661	T3	Deficiency anemia	Hematology	4.43	1	5.91	10	–	1.96	1	Gastroretentive drug delivery formulation
662	T3	Cutaneous ulcers	Dermatology	4.43	5	1.67	3.98	–	8.25	1	RGTA®
663	T3	chemotherapy-induced gastrointestinal mucositi	Gastroenterology	4.43	8	0	0.6	–	8.25	1	MultiBiotic™
664	T3	Cystic Disease Of Lung	Respiratory	4.42	1	3.95	9.96	–	2.02	1	ALBENDAZOLE
665	T3	Spasticity, severe	Neurology/CNS	4.42	5	3.73	1.2	–	8.25	1	Lioresal® Intrathecal
666	T3	Diabetes, type 1	Metabolic & Endocrine	4.41	1.5	5.48	10	–	1.28	1	DBLG1
667	T3	Carcinoma	Oncology	4.4	1	5.48	10	–	2.63	1	Alertix TK1 ELISA
668	T3	Varicella Zoster Infection	Infectious Disease	4.4	2.5	4.23	6.79	–	5.69	1	FAMCICLOVIR
669	T3	Acute bronchitis with bronchospasm	Respiratory	4.4	5	3.33	2	–	7.23	2	Ambroxol Hydrochloride
670	T3	At increased risk for surgical blood loss	Oncology	4.4	5	3.33	2	–	7.23	2	DENOSUMAB
671	T3	Pre-cancerous dysplasia	Oncology	4.4	5	3.33	2	–	7.23	2	VTP-200
672	T3	Via urogenital tract	Infectious Disease	4.4	5	3.33	2	–	7.23	2	OFLOXACIN
673	T3	neck-shoulder-arm syndrome	Rare/Genetic	4.4	5	3.33	2	–	7.67	2	HP-3150
674	T3	Excessive Bleeding		4.39	5	4.53	0	–	8.25	1	AMINOCAPROIC ACID
675	T3	Radiation-Induced Dermatitis	Oncology	4.38	1	6.59	10	–	0	1	LUT-014
676	T3	Melanoma-Pancreatic Cancer Syndrome	Oncology	4.37	1	6.54	10	–	0.52	1	Botensilimab / AGEN1181
677	T3	Metastatic Breast Carcinoma in the Brain	Oncology	4.36	1	6.51	10	–	0	3	Ferumoxytol x IRINOTECAN SUCROSOFATE
678	T3	Metastatic Breast Carcinoma in the Liver	Oncology	4.36	1	6.51	10	–	0	2	MELPHALAN x ERIBULIN x VINORELBINE x CAPECITABINE
679	T3	Enzootic disease	Infectious Disease	4.36	5	1.67	3.63	–	8.25	1	HYOGEN
680	T3	Rheumatoid arthritis	Neurology/CNS	4.35	1	6.02	10	–	1.92	1	Atrosab
681	T3	Ovarian Carcinoma	Oncology	4.33	1	4.38	10	–	0.16	1	PACLITAXEL
682	T3	Malignant lung tumors	Oncology	4.33	1	4.52	9.5	–	0.78	1	EmboCept S DSM 50 μm
683	T3	Xerostomia caused by ionizing radiation	Oncology	4.33	2	4.52	9.8	–	1.54	1	AAV-AQP1
684	T3	Bladder Infections	Infectious Disease	4.33	5	4.34	0.6	–	6.51	3	FLOXACILLIN
685	T3	Advanced Renal Cell Carcinoma	Oncology	4.32	1	4.19	9.81	–	1.62	1	Sapanisertib (TAK-228; MLN0128; INK128)
686	T3	Diabetes, early-onset	Metabolic & Endocrine	4.31	2	4.41	10	–	2.04	1	IMCY-0098
687	T3	Established	Metabolic & Endocrine	4.31	2	4.41	10	–	1.28	1	TOL-3021
688	T3	large B-cell lymphoma	Oncology	4.3	1	3.96	9.29	5	0.61	1	AXICABTAGENE CILOLEUCEL
689	T3	eye disease	Ophthalmology	4.3	1	5.21	9.2	–	3.61	1	ANGICYTE
690	T3	Melanoma	Oncology	4.3	1	5.86	10	5	0.1	1	Tafinlar x Mekinist
691	T3	Dementia associated with Parkinson's Disease	Neurology/CNS	4.3	1	5.98	10	–	0.9	1	NBI-1117567
692	T3	Acute and chronic cholecystitis		4.29	5	3.33	2	–	5.95	4	AmnioWrap2
693	T3	Irritable Bowel Syndrome	Gastroenterology	4.28	1	5.63	9.31	–	2.45	1	VIBEGRON
694	T3	Venous reflux	Gastroenterology	4.28	1	5.34	9.56	–	2.71	1	VENCLOSE RF Ablation System
695	T3	Leukemia, B-Cell	Oncology	4.27	5	4.17	4.89	–	5.69	1	FIT-CD19
696	T3	Squamous Cell Carcinoma of Head and Neck	Oncology	4.26	3	3.58	9.46	–	0.57	1	AVASOPASEM MANGANESE
697	T3	Chronic Kidney Disease	Nephrology/Urology	4.26	1	5.73	10	–	1.12	1	MEZAGITAMAB
698	T3	Hyperphosphatemia due to chronic kidney diseas	Nephrology/Urology	4.26	1	5.73	10	–	1.12	1	TENAPANOR HYDROCHLORIDE
699	T3	Metastatic Urothelial Carcinoma	Oncology	4.25	1	6.41	8.62	–	0	30	ENFORTUMAB VEDOTIN
700	T3	Mite Infestations		4.25	5	2.09	2.92	–	7.67	2	I-LID ’N LASH PRO
701	T3	rabbit haemorrhagic disease (rabbit)	Infectious Disease	4.25	5	2.5	2	–	8.25	1	FatrovaxRHD
702	T3	Multiple stab wounds		4.24	5	2	2	5	8.25	1	Flaminal Hydro
703	T3	Depressive Disorder	Psychiatry	4.23	1	5.63	10	–	1.04	1	BFB-101
704	T3	Mantle cell lymphoma refractory	Oncology	4.2	1	5.74	8.45	–	2.47	1	CT125A cells
705	T3	Functional bowel disorder	Gastroenterology	4.18	1	5.29	9.31	–	1.69	3	TRIMEBUTINE
706	T3	Foot drop	Neurology/CNS	4.17	1	5.37	10	–	1.17	1	Fesia Walk
707	T3	biofilm disease		4.17	5	2.5	2	–	7.23	2	StemDetox
708	T3	Vaginal Infections	Infectious Disease	4.16	5	3.33	2	–	4.44	9	Clogìn mousse
709	T3	Adult Myelodysplastic Syndrome	Hematology	4.15	1	3.95	9.32	–	0.59	1	CLOFARABINE
710	T3	Myelodysplastic Syndromes	Hematology	4.15	1	3.95	9.32	–	0.59	1	Biolevox Neuro
711	T3	childhood myelodysplastic syndrome	Oncology	4.15	1	3.95	9.32	–	0.59	1	GUADECITABINE
712	T3	Radiation thrombocytopenia	Hematology	4.14	7	0.79	0	–	8.25	1	Thrombosomes
713	T3	Abdominal and gastrointestinal infections	Immunology & Inflammation	4.14	5	2.57	1.4	–	8.25	1	Meropenem for Injection USP
714	T3	Biliary pain	Gastroenterology	4.13	5	2.92	0	–	8.25	1	Dolocalma
715	T3	Atopic disorders	Immunology & Inflammation	4.13	1	5.35	9.61	–	0.7	3	DUPILUMAB
716	T3	Fractures	Cardiovascular	4.13	7	0.78	0	–	8.25	1	CF-M801
717	T3	Urinary Bladder, Overactive		4.13	1	5.63	8.15	–	2.12	5	OXYBUTYNIN
718	T3	Abrasions		4.11	5	2	2	–	8.25	1	CoMatryx OTC
719	T3	Airways	Immunology & Inflammation	4.11	5	2	2	–	8.25	1	LEVODROPROPIZINE
720	T3	Atherosclerotic Cardiovascular Disease	Cardiovascular	4.11	5	2	2	–	8.25	1	BioMimics 3D Vascular Stent System
721	T3	Avian infectious bronchitis	Infectious Disease	4.11	5	2	2	–	8.25	1	Avian Newcastle Disease and Avian Infectious Bronchitis Combined Live Vaccines
722	T3	Bacterial infection caused by Klebsiella pneum	Infectious Disease	4.11	5	2	2	–	8.25	1	Compound Cefalexin Capsules
723	T3	Bacterial infection caused by Streptococcus mi	Infectious Disease	4.11	5	2	2	–	8.25	1	Compound Cefalexin Capsules
724	T3	Bleeding mild to severe		4.11	5	2	2	–	8.25	1	NuStat Flex XR
725	T3	Bloodstream infections	Infectious Disease	4.11	5	2	2	–	8.25	1	DISQVER
726	T3	CT of thoracic and lumbar spine		4.11	5	2	2	–	8.25	1	KONG®-TL VBR
727	T3	Carbamylphosphate synthetase deficiency	Metabolic & Endocrine	4.11	5	2	2	–	8.25	1	SODIUM PHENYLBUTYRATE
728	T3	Cardiomyopathy, Alcoholic	Cardiovascular	4.11	5	2	2	–	8.25	1	ACAMPROSATE
729	T3	Cerebral trauma	Neurology/CNS	4.11	5	2	2	–	8.25	1	Brecetam Inj.
730	T3	Cervical disc herniation	Women's & Reproductive Health	4.11	5	2	2	–	8.25	1	DiscoGel
731	T3	Chemotherapy induced peripheral neuropathy	Neurology/CNS	4.11	5	2	2	–	8.25	1	Rition
732	T3	Chronic intestinal amoebiasis	Gastroenterology	4.11	5	2	2	–	8.25	1	Axcel Metronidazole
733	T3	Chronic ischemic heart disease	Cardiovascular	4.11	5	2	2	–	8.25	1	Fructose Sodium Diphosphate
734	T3	Chronic pain due to trauma		4.11	5	2	2	–	8.25	1	proff® pain gel
735	T3	Chronic persistent hepatitis	Infectious Disease	4.11	5	2	2	–	8.25	1	Liganlong Granules
736	T3	Complicated infection	Infectious Disease	4.11	5	2	2	–	8.25	1	Armillarisin A Injection
737	T3	Diabetic glomerulopathy	Metabolic & Endocrine	4.11	5	2	2	–	8.25	1	CALCIUM DOBESILATE
738	T3	Digestive System Hemorrhage		4.11	5	2	2	–	8.25	1	Carbazochrome Sodium Sulfonate for Injection
739	T3	Digestive problems		4.11	5	2	2	–	8.25	1	Egaver
740	T3	Disease of blood AND/OR blood-forming organ		4.11	5	2	2	–	8.25	1	Colla Corii Asini
741	T3	Diseases of the musculoskeletal system and con	Musculoskeletal	4.11	5	2	2	–	8.25	1	Traditional Chinese Medicine (TCM) products
742	T3	Eczematous otitis externa	Dermatology	4.11	5	2	2	–	8.25	1	DermOtic Oil Ear Drops
743	T3	Egg drop syndrome	Rare/Genetic	4.11	5	2	2	–	8.25	1	Gallimune 302 ND+IB+EDS
744	T3	Febrile disorders	Hematology	4.11	5	2	2	–	8.25	1	Beijing Tong Ren Tang Angong Niuhuang Wan
745	T3	Focal lesions, multiple		4.11	5	2	2	–	8.25	1	Episealer Talus
746	T3	Gangrenous disorder		4.11	5	2	2	–	8.25	1	EPIFLO
747	T3	Gonococcal infection (acute) of upper genitour	Gastroenterology	4.11	5	2	2	–	8.25	1	SOMATOSTATIN
748	T3	Helminthiases		4.11	5	2	2	–	8.25	1	Thiaben®
749	T3	Idiopathic postprandial syndrome	Rare/Genetic	4.11	5	2	2	–	8.25	1	Combizym
750	T3	Imbalance	Gastroenterology	4.11	5	2	2	–	8.25	1	Triobiotix 360
751	T3	Immunoglobulin G deficiency	Immunology & Inflammation	4.11	5	2	2	–	8.25	1	Human Immunoglobulin (pH4) for Intravenous Injection, Freeze-dried
752	T3	Infection by Taenia taeniaeformis	Infectious Disease	4.11	5	2	2	–	8.25	1	Albel
753	T3	Inflammatory bone lesions	Rare/Genetic	4.11	5	2	2	–	8.25	1	Bonopty® Bone Biopsy System
754	T3	Lactation Disorders	Dermatology	4.11	5	2	2	–	8.25	1	PARNAPARIN SODIUM
755	T3	Mouth Diseases	Immunology & Inflammation	4.11	5	2	2	–	8.25	1	Anginova®
756	T3	Neoplasms, Post-Traumatic		4.11	5	2	2	–	8.25	1	BROMELAINS
757	T3	Neoplasms, Radiation-Induced		4.11	5	2	2	–	8.25	1	CAMISAN
758	T3	Nickel allergy	Immunology & Inflammation	4.11	5	2	2	–	8.25	1	Nickel treatment
759	T3	Oedema due to renal disease		4.11	5	2	2	–	8.25	1	Subunit Vaccines against Oedema Disease
760	T3	Other disorders of synovium and tendon	Musculoskeletal	4.11	5	2	2	–	8.25	1	OSTENIL® TENDON
761	T3	Pain in ankle and joints of foot	Musculoskeletal	4.11	5	2	2	–	8.25	1	Zolben®
762	T3	Partial seizures with secondary generalization	Neurology/CNS	4.11	5	2	2	–	8.25	1	LACOSAMIDE
763	T3	Pododermatitis circumscripta		4.11	5	2	2	–	8.25	1	Reacorin
764	T3	Porcine Reproductive and Respiratory Syndrome	Respiratory	4.11	5	2	2	–	8.25	1	Rui Lan An
765	T3	Post-herpetic polyneuropathy		4.11	5	2	2	–	8.25	1	ASENAPINE
766	T3	Postpartum mood disorder		4.11	5	2	2	–	8.25	1	Blues Away
767	T3	Preinfarction syndrome	Rare/Genetic	4.11	5	2	2	–	8.25	1	Troxerutin Tablets
768	T3	Preventing infection of immunocompromised pati	Infectious Disease	4.11	5	2	2	–	8.25	1	CEFPIROME
769	T3	Protozoal diseases		4.11	5	2	2	–	8.25	1	MEDAZOL®
770	T3	Respiratory tract inflammation	Immunology & Inflammation	4.11	5	2	2	–	8.25	1	Prospan
771	T3	Rhinotracheitis	Infectious Disease	4.11	5	2	2	–	8.25	1	Jinyu Baoling
772	T3	Sequelae of disorders	Neurology/CNS	4.11	5	2	2	–	8.25	1	Pyritinol Hydrochloride Tablets
773	T3	Skin infections, chronic	Dermatology	4.11	5	2	2	–	8.25	1	BPMatrix
774	T3	Spinal Enthesopathy, Thoracolumbar Region		4.11	5	2	2	–	8.25	1	True Spinal Fixation System
775	T3	Stabilization		4.11	5	2	2	–	8.25	1	GoPLF!
776	T3	Strangles		4.11	5	2	2	–	8.25	1	Strangvac
777	T3	T cell dysfunction		4.11	5	2	2	–	8.25	1	Qu’Ao
778	T3	Wound Dehiscence		4.11	5	2	2	–	8.25	1	ABCcolla® Collagen Membrane
779	T3	inflammation of the tonsils	Immunology & Inflammation	4.11	5	2	2	–	8.25	1	Axetine
780	T3	meningitis/encephalitis	Neurology/CNS	4.11	5	2	2	–	8.25	1	QIAstat-Dx Meningitis/Encephalitis Panel
781	T3	menstruation pain		4.11	5	2	2	–	8.25	1	WeWoThom Premium
782	T3	open wounds		4.11	5	2	2	–	8.25	1	Chuangfukang collagen sponge
783	T3	post traumatic skin infection	Dermatology	4.11	5	2	2	–	8.25	1	DEBRICHEM
784	T3	digestive system diseases		4.1	5	3.2	2	–	4.06	10	LIPOIC ACID, ALPHA
785	T3	Metastatic Liver Carcinoma	Oncology	4.08	1	5.49	10	–	0	1	Edison Histotripsy System
786	T3	carcinoma of the brain	Infectious Disease	4.08	1	5.49	10	–	0	1	Ornidazole Injection
787	T3	Atopic Dermatitis	Dermatology	4.08	1	5.18	9.61	–	1.01	2	ASN008
788	T3	feline immunodeficiency virus infection	Immunology & Inflammation	4.08	1	4.75	9.7	–	1.45	4	Speed Duo FeLV/FIV
789	T3	infected wound	Infectious Disease	4.08	5	2	2	5	5.95	4	Flaminal Hydro
790	T3	Transfusion dependent anemia	Hematology	4.07	5	4.14	2.16	5	6.5	4	IMETELSTAT
791	T3	Dermatoses	Immunology & Inflammation	4.06	5	3.33	0	–	8.25	1	Betamethasone Dipropionate Cream
792	T3	Erosion	Women's & Reproductive Health	4.05	5	0.94	3.11	–	8.25	1	Chlorhexidine Acetate Solution
793	T3	Cystic Fibrosis	Respiratory	4.04	1	2.29	9.96	–	2.02	1	AP-PA02
794	T3	Cystic fibrosis respiratory infection suppress	Respiratory	4.04	1	2.29	9.96	–	2.02	1	CMTX-101
795	T3	Leukodystrophy, Metachromatic	Metabolic & Endocrine	4.04	5	4.04	0	–	8.25	1	ATIDARSAGENE AUTOTEMCEL
796	T3	Clostridium Infections	Infectious Disease	4.04	4	2.08	4.87	–	6.1	1	OG716
797	T3	Cardiovascular lesions of pinta	Cardiovascular	4.03	5	2	2	–	7.67	2	Spex™ LP
798	T3	Circulatory Disorders		4.03	5	2	2	–	7.23	2	Angipax
799	T3	Hypervascular lesion	Oncology	4.03	5	2	2	–	7.23	2	Ekobi® Embolization Microspheres
800	T3	Osteochondral defects		4.03	5	2	2	–	7.23	2	TnRhuCartilage
801	T3	Skin and subcutaneous tissue disorders	Dermatology	4.03	5	2	2	–	7.67	2	Altrazeal®
802	T3	Cervix uteri cancer	Oncology	4.02	2	3.29	10	–	1.41	1	Photodynamic Therapy
803	T3	HBV infection	Infectious Disease	4.02	1	4.5	9.7	–	2.21	2	GongMing Anti-HIV Injection
804	T3	Melanoma	Oncology	4.0	1	5.2	10	–	0.1	1	ENCORAFENIB
805	T3	Edema due to hypoproteinemia	Gastroenterology	4.0	5	0.77	3.09	–	8.25	1	Torasemide for Injection
806	T3	Primary Myelofibrosis	Hematology	3.99	3.5	3.67	7.5	0	2.85	2	Zilurgisertib x RUXOLITINIB
807	T3	Advanced Melanoma	Oncology	3.98	1	4.53	10	5	0.85	1	BI-765063
808	T3	Bile acid synthesis disorder		3.97	5	3.57	0.6	–	7.67	1	CHOLIC ACID
809	T3	inborn disorder of bile acid synthesis	Metabolic & Endocrine	3.97	5	3.57	0.6	–	7.23	1	CHOLIC ACID
810	T3	Meniscus tear		3.97	5	2	2	–	6.51	3	StemArt
811	T3	Periodontal Diseases	Oncology	3.97	5	2	2	–	6.82	3	NovaBone Porous Granules
812	T3	Oesophageal squamous cell carcinoma	Oncology	3.95	1	3.82	10	–	2.63	1	TISLELIZUMAB
813	T3	Human immunodeficiency virus infection	Immunology & Inflammation	3.95	1	4.42	9.57	4.21	0	37	CABOTEGRAVIR x RILPIVIRINE
814	T3	Acute tuberculosis	Neurology/CNS	3.93	1	1.67	10	–	2.22	1	Sodium Aminosalicylate for Injection
815	T3	bacterial infection	Infectious Disease	3.93	1	4.73	10	–	0.7	1	CEFIDEROCOL
816	T3	Other infectious diseases (B99)	Infectious Disease	3.93	5	2	2	–	6.19	4	Thermostable Single-Shot Vaccines
817	T3	Advanced breast cancer	Oncology	3.92	1	4.92	10	–	0	1	Vistusertib (AZD2014)
818	T3	COVID-19	Respiratory	3.92	1	4.91	10	–	0.21	1	VARESPLADIB
819	T3	Anaplastic thyroid cancer	Oncology	3.91	1	4.88	10	–	0.52	1	CFT1946
820	T3	Colorectal cancer	Oncology	3.91	1	4.88	10	–	0.52	1	BALSTILIMAB
821	T3	Gastric Hodgkin Lymphoma	Oncology	3.91	1	4.61	10	–	1.49	1	SINTILIMAB
822	T3	Gastric cancer	Oncology	3.91	1	4.61	10	–	1.49	1	ZIMBERELIMAB
823	T3	Alzheimer dementia (AD)	Neurology/CNS	3.91	1	4.73	10	–	0	7	RGn530
824	T3	Leptin Receptor	Metabolic & Endocrine	3.89	5	4.43	0.95	–	7.23	2	SETMELANOTIDE
825	T3	Spinal Degenerative Disorder		3.89	5	2	2	–	6.68	5	INERTIA® Deformity Correxxion System
826	T3	Umbilical cord infection	Infectious Disease	3.88	5	2.66	0	–	8.25	1	CHLORHEXIDINE
827	T3	Advanced Lymphoma	Oncology	3.82	1	2.29	9.29	–	1.05	1	Voxtalisib (SAR245409; XL765)
828	T3	Pulmonary fibrosis due to recurrent infections	Respiratory	3.81	1	1.24	9.96	–	2.02	1	Meropenem for Injection USP
829	T3	Edema due to hepatic disease	Gastroenterology	3.81	5	1.05	1.81	–	8.25	1	Bumetanide Injection USP
830	T3	Edema due to renal disease	Nephrology/Urology	3.81	5	1.05	1.81	–	8.25	1	Bumetanide Injection USP
831	T3	HIV-1 infection	Infectious Disease	3.79	1	3.77	8.98	–	3.08	1	HIV1/2 antibody detection kits
832	T3	Partial thickness wound		3.79	5	2	2	–	4	9	Restrata
833	T3	Mycobacterial infections	Infectious Disease	3.78	5	1.62	3.65	–	8.25	1	PaxView® TB/NTM-ID MPCR-ULFA Ex Kit
834	T3	Noncancerous tumors	Oncology	3.78	5	2	2	–	4.82	10	Sniper® Balloon Occlusion Microcatheter
835	T3	Posterior Cord Syndrome	Rare/Genetic	3.74	5	0.42	5.04	–	8.25	1	DRX9000
836	T3	RICKETTSIAL INFECTIONS	Infectious Disease	3.72	5	1.25	2	–	5.95	4	Febrile Antigen Kit
837	T3	Hepatitis C Infection	Infectious Disease	3.65	1	3.48	9.57	–	1.76	1	Hepatitis E diagnostic kit
838	T3	Autoinflammation		3.62	5	2.37	0	–	6.94	4	i.Mune® CD4/CD8
839	T3	methionine deficiency	Metabolic & Endocrine	3.61	5	2.06	2.08	–	8.25	1	Methionine and Vitamin B1 for Injection
840	T3	Fistulas		3.6	5	2.41	0	–	5.49	5	ATZ STEM CELL THERAPY
841	T3	COVID-19	Infectious Disease	3.57	1	3.63	10	–	0	26	Zofin
842	T3	Ocular Vascular Disorder	Cardiovascular	3.52	1	5.54	3.31	–	6.1	1	FLUOROMETHOLONE ACETATE
843	T3	Diaphyseal fracture		3.46	5	1.14	0	–	8.25	1	Point Contact Locking Plate
844	T3	Pancreatic cancer	Oncology	3.45	1	5.79	5.17	5	0.45	1	DARATUMUMAB
845	T3	Lesions in the white matter		3.43	5	1.92	1.2	–	8.25	1	Spur® Peripheral Retrievable Scaffold System
846	T3	Urinary Stone	Nephrology/Urology	3.43	5	0.56	0.6	–	8.25	1	Batugin
847	T3	Proximal Femoral Fractures		3.4	5	2	0.95	–	8.25	1	RoSA - Rotationstable Screw Anchor
848	T3	No structural defects		3.35	5	1	2	–	8.25	1	ProText
849	T3	Paralysis vocal cord	Neurology/CNS	3.14	5	0	2.08	–	8.25	1	Silk Voice
850	T3	Oral mucosal disorder		3.13	5	0.42	0	–	6.82	3	Autologous Cultured Oral Mucosal Epithelium
851	T3	Bone defects	Musculoskeletal	2.95	5	2.74	0	–	1.87	33	OsteoXcell VM

The indication atlas

Opportunity × crowdedness — where the white-space is

Each scored indication placed by competitive crowdedness (columns, from programme and sponsor counts) against opportunity index (rows). The highlighted top-left cell — high opportunity, few competitors — is the blue-sky white-space corner.

Open (<2.5)

Moderate (2.5–5)

Crowded (5–10)

High (6.5+)

Subacute necrotizing eSkin ulcer due to variHypertension-AssociateProgressive hearing loRare epilepsyExtensively Drug-Resis+35

Drug Abusemitochondrial respiratHigh Grade B-Cell LympPrimary combined hyperTriple hit lymphomaCholestatic hepatitis+18

Locally Recurrent Breagynecologic cancerNUT CarcinomaB Acute Lymphoblastic Hematological neoplasmSystemic Inflammatory

Mid (5–6.5)

Subcutaneous Tissuemuscular dystrophy-dysPolyneuropathy due to Parkinson's disease wiCapillary MalformationAdenovirus Infection+205

Fuchs' endothelial dysResistant hypertensivemonogenic diseaseHand-Foot SyndromeMetastatic Prostatic ATakotsubo syndrome+111

hematopoietic/lymphoidPrematurity of infantLung DiseasesSevere asthmaObstructive cardiomyoppulmonary heart diseas+107

Lower (<5)

Spinal tumorsACTH Syndrome, EctopicGLUT1 Deficiency SyndrIntestinal infections IgE-mediated allergic degenerative brain dis+147

Marburg diseaseAcute respiratory infeRetinal angiopathyVasomotor rhinitisSalmonella infectionChylomicronemia syndro+44

Chronic intestinal faiDiarrhea post chemothedisease of the bloodSquamous Intraepithelifertility disordersCholangiocarcinoma+130

Sources & method

Disease set: every disease in our resolved catalogue of 25,088 that is a high-confidence, auto-resolved concept and carries recorded drug-evidence in our pipeline, after removing exact duplicates, concepts with no named drug asset, and a curated list of non-indication concepts (procedures, bare anatomy and umbrella grouping terms) — 851 indications. No external list is used. Assets are attached to each disease through the resolver's own key (each drug-evidence row's resolved-disease keyword maps to the same resolved concept), not by fuzzy name — so 851 of 851 diseases surface their real programmes. For the treatment-landscape, genetic, tractability and research axes, each disease is also matched to an Open Targets node via every ontology id the resolver holds (primary, canonical, source) with an Open Targets name-search fallback; 492 of 851 resolved to a node. The therapy-gap axis combines Open Targets and our own most-advanced phase; tractability blends Open Targets genetic-association and per-target druggability with our own druggable-genome tier; research is Open Targets literature co-occurrence volume; pipeline momentum reads trial status (advancing vs terminated) from our data; whitespace is a log function of the programme count; prevalence is Orphanet (orphadata product9_prev). Opportunity index computed by us; a research signal, not clinical guidance.